Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
21,900 | 2014-02-12 00:00:00 UTC | Sector Update: Financials | AB | https://www.nasdaq.com/articles/sector-update-financials-2014-02-12 | null | null | Financial shares were idle in Wednesday's pre-market trade as investors absorb positive China trade data with few other economic indicators on tap.
In financial stocks news, NewStar Financial, Inc. ( NEWS ), a specialized commercial finance company, today reported consolidated net income of $6.4 million, or $0.12 per d... | And, Alliance Bernstein ( AB ), an investment management firm, says Q4 adjusted net income per unit rose 50% to $0.60 per share from a year ago, as revenue rose on higher performance-based and base fees, Bernstein Research Services revenues and investment gains. Financial shares were idle in Wednesday's pre-market trad... | And, Alliance Bernstein ( AB ), an investment management firm, says Q4 adjusted net income per unit rose 50% to $0.60 per share from a year ago, as revenue rose on higher performance-based and base fees, Bernstein Research Services revenues and investment gains. The views and opinions expressed herein are the views and... | Financial shares were idle in Wednesday's pre-market trade as investors absorb positive China trade data with few other economic indicators on tap. And, Alliance Bernstein ( AB ), an investment management firm, says Q4 adjusted net income per unit rose 50% to $0.60 per share from a year ago, as revenue rose on higher p... | Financial shares were idle in Wednesday's pre-market trade as investors absorb positive China trade data with few other economic indicators on tap. And, Alliance Bernstein ( AB ), an investment management firm, says Q4 adjusted net income per unit rose 50% to $0.60 per share from a year ago, as revenue rose on higher p... |
21,901 | 2014-02-10 00:00:00 UTC | Can Western Union (WU) Surprise This Earnings Season? - Analyst Blog | AB | https://www.nasdaq.com/articles/can-western-union-wu-surprise-this-earnings-season-analyst-blog-2014-02-10 | null | null | We expect money transferor Western Union Co. ( WU ) to beat expectations when it reports fourth-quarter 2013 results on Feb 11.
Why a Likely Positive Surprise?
Our proven model shows that Western Union is likely to beat earnings because it has the right combination of two key ingredients.
Positive Zacks ESP: Expected S... | AllianceBernstein Holding L.P. ( AB ), Earnings ESP of +2.33% and a Zacks Rank #3. ALLIANCEBERNSTN (AB): Free Stock Analysis Report VENTAS INC (VTR): Free Stock Analysis Report WALKER & DUNLOP (WD): Free Stock Analysis Report WESTERN UNION (WU): Free Stock Analysis Report To read this article on Zacks.com click here. T... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report VENTAS INC (VTR): Free Stock Analysis Report WALKER & DUNLOP (WD): Free Stock Analysis Report WESTERN UNION (WU): Free Stock Analysis Report To read this article on Zacks.com click here. AllianceBernstein Holding L.P. ( AB ), Earnings ESP of +2.33% and a Zacks Rank #3. W... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report VENTAS INC (VTR): Free Stock Analysis Report WALKER & DUNLOP (WD): Free Stock Analysis Report WESTERN UNION (WU): Free Stock Analysis Report To read this article on Zacks.com click here. AllianceBernstein Holding L.P. ( AB ), Earnings ESP of +2.33% and a Zacks Rank #3. P... | AllianceBernstein Holding L.P. ( AB ), Earnings ESP of +2.33% and a Zacks Rank #3. ALLIANCEBERNSTN (AB): Free Stock Analysis Report VENTAS INC (VTR): Free Stock Analysis Report WALKER & DUNLOP (WD): Free Stock Analysis Report WESTERN UNION (WU): Free Stock Analysis Report To read this article on Zacks.com click here. T... |
21,902 | 2013-10-30 00:00:00 UTC | Allianceberstein Holding L.P. (AB) Ex-Dividend Date Scheduled for October 31, 2013 | AB | https://www.nasdaq.com/articles/allianceberstein-holding-lp-ab-ex-dividend-date-scheduled-october-31-2013-2013-10-30 | null | null | Allianceberstein Holding L.P. ( AB ) will begin trading ex-dividend on October 31, 2013. A cash dividend payment of $0.4 per share is scheduled to be paid on November 21, 2013. Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an -2.44% decreas... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. AB is a part of the Finance sector, which includes companies such as Franklin Resources, Inc. ( BEN ) and AMERIPRISE FINANCIAL SERVICES, INC. ( AMP ). Zacks Investment Research reports AB's forecasted earnings ... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Allianceberstein Holding L.P. ( AB ) will begin trading ex-dividend on Octob... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of AB was $22.39, representing a -18.22% decrease from the 52 week high of $27.38 and a 42.79% increase over the 52 week low of $15.68. For more information on the declarati... | Allianceberstein Holding L.P. ( AB ) will begin trading ex-dividend on October 31, 2013. Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. AB's current earnings per share, an indicator of a company's profitability, is $1.36. |
21,903 | 2013-10-24 00:00:00 UTC | Sector Update: Financial Shares Higher; AllianceBernstein Beats Street View with Q3 Results | AB | https://www.nasdaq.com/articles/sector-update-financial-shares-higher-alliancebernstein-beats-street-view-q3-results-2013 | null | null | Top Financial Shares:
JPM: +0.66%
BAC: flat
WFC: flat
C: +0.62%
USB: -0.55%
Financial shares are flat to higher pre-market trade after a fairly soft session yesterday and on a rise in October's China manufacturing Purchasing Managers Index.
In financial stocks news, T. Rowe Price Group, Inc. ( TROW ) reported Q3 net re... | And, AllianceBernstein ( AB ) said its Q3 adjusted earnings rose to $0.40 per share from $0.36 the year earlier, ahead of the $0.39 average Capital IQ analyst estimate. Financial shares are flat to higher pre-market trade after a fairly soft session yesterday and on a rise in October's China manufacturing Purchasing Ma... | And, AllianceBernstein ( AB ) said its Q3 adjusted earnings rose to $0.40 per share from $0.36 the year earlier, ahead of the $0.39 average Capital IQ analyst estimate. In financial stocks news, T. Rowe Price Group, Inc. ( TROW ) reported Q3 net revenues of $884.4 million, net income of $270.3 million, and diluted earn... | And, AllianceBernstein ( AB ) said its Q3 adjusted earnings rose to $0.40 per share from $0.36 the year earlier, ahead of the $0.39 average Capital IQ analyst estimate. In financial stocks news, T. Rowe Price Group, Inc. ( TROW ) reported Q3 net revenues of $884.4 million, net income of $270.3 million, and diluted earn... | And, AllianceBernstein ( AB ) said its Q3 adjusted earnings rose to $0.40 per share from $0.36 the year earlier, ahead of the $0.39 average Capital IQ analyst estimate. Financial shares are flat to higher pre-market trade after a fairly soft session yesterday and on a rise in October's China manufacturing Purchasing Ma... |
21,904 | 2013-09-04 00:00:00 UTC | Insiders Buy Shares at Valeant Pharmaceuticals and Energy Recovery | AB | https://www.nasdaq.com/articles/insiders-buy-shares-valeant-pharmaceuticals-and-energy-recovery-2013-09-04 | null | null | Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside sales and purchases filed with the SEC on Tuesday, September 3, 2013.
Notable Purchases:
Fred Hassan, a director at multinational specialty pharmaceutical company Valeant Pharmaceutical International ( VRX ), bought 51,000 ... | Scott Schoen, a director at investment firm AllianceBernstein Holding ( AB ), bought 50,000 shares of company stock for $980,640. At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and tec... | Here's a look at the most significant inside sales and purchases filed with the SEC on Tuesday, September 3, 2013. Notable Purchases: Fred Hassan, a director at multinational specialty pharmaceutical company Valeant Pharmaceutical International ( VRX ), bought 51,000 shares of company stock for $5,049,459. Scott Schoen... | Here's a look at the most significant inside sales and purchases filed with the SEC on Tuesday, September 3, 2013. Notable Purchases: Fred Hassan, a director at multinational specialty pharmaceutical company Valeant Pharmaceutical International ( VRX ), bought 51,000 shares of company stock for $5,049,459. Source: Insi... | Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes An important note from Jonathan Moreland, founder of Insider Insights : In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monit... |
21,905 | 2013-08-19 00:00:00 UTC | Company News for August 19, 2013 - Corporate Summary | AB | https://www.nasdaq.com/articles/company-news-for-august-19-2013-corporate-summary-2013-08-19 | null | null | • Bally Technologies Inc. (NYSE: BYI ) reported fourth quarter earnings per share of $0.95, marginally higher than the Zacks Consensus Estimate of $0.93
• Applied Materials, Inc. (NASDAQ: AMAT ) posted fiscal third quarter earnings per share of $0.18, lower than the Zacks Consensus Estimate of $0.19
• Aspen Technology,... | • Bally Technologies Inc. (NYSE: BYI ) reported fourth quarter earnings per share of $0.95, marginally higher than the Zacks Consensus Estimate of $0.93 • Applied Materials, Inc. (NASDAQ: AMAT ) posted fiscal third quarter earnings per share of $0.18, lower than the Zacks Consensus Estimate of $0.19 • Aspen Technology,... | • Bally Technologies Inc. (NYSE: BYI ) reported fourth quarter earnings per share of $0.95, marginally higher than the Zacks Consensus Estimate of $0.93 • Applied Materials, Inc. (NASDAQ: AMAT ) posted fiscal third quarter earnings per share of $0.18, lower than the Zacks Consensus Estimate of $0.19 • Aspen Technology,... | • Bally Technologies Inc. (NYSE: BYI ) reported fourth quarter earnings per share of $0.95, marginally higher than the Zacks Consensus Estimate of $0.93 • Applied Materials, Inc. (NASDAQ: AMAT ) posted fiscal third quarter earnings per share of $0.18, lower than the Zacks Consensus Estimate of $0.19 • Aspen Technology,... | • Bally Technologies Inc. (NYSE: BYI ) reported fourth quarter earnings per share of $0.95, marginally higher than the Zacks Consensus Estimate of $0.93 • Applied Materials, Inc. (NASDAQ: AMAT ) posted fiscal third quarter earnings per share of $0.18, lower than the Zacks Consensus Estimate of $0.19 • Aspen Technology,... |
21,906 | 2013-08-07 00:00:00 UTC | Allianceberstein Holding L.P. (AB) Ex-Dividend Date Scheduled for August 08, 2013 | AB | https://www.nasdaq.com/articles/allianceberstein-holding-lp-ab-ex-dividend-date-scheduled-august-08-2013-2013-08-07 | null | null | Allianceberstein Holding L.P. ( AB ) will begin trading ex-dividend on August 08, 2013. A cash dividend payment of $0.41 per share is scheduled to be paid on August 29, 2013. Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 7.89% increase o... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. AB is a part of the Finance sector, which includes companies such as Franklin Resources, Inc. ( BEN ) and AMERIPRISE FINANCIAL SERVICES, INC. ( AMP ). Zacks Investment Research reports AB's forecasted earnings ... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Allianceberstein Holding L.P. ( AB ) will begin trading ex-dividend on Augus... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of AB was $22.76, representing a -16.87% decrease from the 52 week high of $27.38 and a 90.62% increase over the 52 week low of $11.94. For more information on the declarati... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. Allianceberstein Holding L.P. ( AB ) will begin trading ex-dividend on August 08, 2013. The previous trading day's last sale of AB was $22.76, representing a -16.87% decrease from the 52 week high of $27.38 and... |
21,907 | 2013-08-01 00:00:00 UTC | Company News for August 1, 2013 - Corporate Summary | AB | https://www.nasdaq.com/articles/company-news-for-august-1-2013-corporate-summary-2013-08-01 | null | null | • AllianceBernstein Holding LP (NYSE: AB ) posted second quarter earnings per share of $0.41, beating the Zacks Consensus Estimate of $0.38
• Amedisys Inc (NASDAQ: AMED ) reported second quarter earnings per share of $0.17, ahead of the Zacks Consensus Estimate of $0.10
• Humana Inc (NYSE: HUM ) posted second quarter e... | • AllianceBernstein Holding LP (NYSE: AB ) posted second quarter earnings per share of $0.41, beating the Zacks Consensus Estimate of $0.38 • Amedisys Inc (NASDAQ: AMED ) reported second quarter earnings per share of $0.17, ahead of the Zacks Consensus Estimate of $0.10 • Humana Inc (NYSE: HUM ) posted second quarter e... | • AllianceBernstein Holding LP (NYSE: AB ) posted second quarter earnings per share of $0.41, beating the Zacks Consensus Estimate of $0.38 • Amedisys Inc (NASDAQ: AMED ) reported second quarter earnings per share of $0.17, ahead of the Zacks Consensus Estimate of $0.10 • Humana Inc (NYSE: HUM ) posted second quarter e... | • AllianceBernstein Holding LP (NYSE: AB ) posted second quarter earnings per share of $0.41, beating the Zacks Consensus Estimate of $0.38 • Amedisys Inc (NASDAQ: AMED ) reported second quarter earnings per share of $0.17, ahead of the Zacks Consensus Estimate of $0.10 • Humana Inc (NYSE: HUM ) posted second quarter e... | • AllianceBernstein Holding LP (NYSE: AB ) posted second quarter earnings per share of $0.41, beating the Zacks Consensus Estimate of $0.38 • Amedisys Inc (NASDAQ: AMED ) reported second quarter earnings per share of $0.17, ahead of the Zacks Consensus Estimate of $0.10 • Humana Inc (NYSE: HUM ) posted second quarter e... |
21,908 | 2013-05-28 00:00:00 UTC | PFG Partners Accountable Health - Analyst Blog | AB | https://www.nasdaq.com/articles/pfg-partners-accountable-health-analyst-blog-2013-05-28 | null | null | Recently, Principal Financial Group Inc. ( PFG ) announced a strategic deal with Md.-based Accountable Health, Inc., under which the latter will provide a wide variety of wellness programs to the business and health plan customers of the former. Moreover, Principal Financial will transfer the ownership of its subsidiar... | Both Accountable Health and Principal Financial are anticipating a seamless transition for the clientele and advisors of the latter. Principal Financial believes that Accountable Health will be able to combine the resources and expertise of both the companies, thus facilitating expansion amid the swiftly transforming a... | Other investment management companies worth considering are AllianceBernstein Holding L.P. ( AB ), GAMCO Investors, Inc. ( GBL ) and Noah Holdings Limited ( NOAH ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report GAMCO INVESTORS (GBL): Free Stock Analysis Report NOAH HLDGS LTD (NOAH): Free Stock Analysis Report PRINCI... | Recently, Principal Financial Group Inc. ( PFG ) announced a strategic deal with Md.-based Accountable Health, Inc., under which the latter will provide a wide variety of wellness programs to the business and health plan customers of the former. Moreover, Principal Financial will transfer the ownership of its subsidiar... | Moreover, Principal Financial will transfer the ownership of its subsidiary - Principal Wellness Company - to Accountable Health. Further, Principal Financial will make financial investment in Accountable Health. Recently, Principal Financial Group Inc. ( PFG ) announced a strategic deal with Md.-based Accountable Heal... |
21,909 | 2013-05-24 00:00:00 UTC | BlackRock Remains Neutral - Analyst Blog | AB | https://www.nasdaq.com/articles/blackrock-remains-neutral-analyst-blog-2013-05-24 | null | null | On May 23, 2013, we reiterated our long-term recommendation on BlackRock, Inc . ( BLK ) at Neutral based on its improved capital deployment activities and acquisition plans. However, an elevated cost structure and high dependence on fee-based revenue are the causes of concern.
Why the Neutral Stance?
BlackRock's first-... | ( AB ), GAMCO Investors, Inc . ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report GAMCO INVESTORS (GBL): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. Further, BlackRock acquired Credit Suisse's E... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report GAMCO INVESTORS (GBL): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. ( AB ), GAMCO Investors, Inc . However, BlackRock's dependence on investment... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report GAMCO INVESTORS (GBL): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. ( AB ), GAMCO Investors, Inc . However, BlackRock's dependence on investment... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report GAMCO INVESTORS (GBL): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. ( AB ), GAMCO Investors, Inc . ( BLK ) at Neutral based on its improved capi... |
21,910 | 2013-05-22 00:00:00 UTC | BlackRock Soars to a New 52-Week High - Analyst Blog | AB | https://www.nasdaq.com/articles/blackrock-soars-to-a-new-52-week-high-analyst-blog-2013-05-22 | null | null | Shares of BlackRock, Inc . ( BLK ) crafted a new 52-week high, touching $293.31 at the beginning of the trading session on May 21, 2013. The closing price of this leading asset manager represents a solid year-to-date return of 38.1%. The average trading volume over the last 3 months was 0.7 million shares.
Despite hitt... | The year-over-year improvement was primarily attributable to top-line growth, partially offset by higher operating expenses. The acquisition will enable BlackRock to acquire MGPA's assets under management worth approximately $12 billion. The results compare favorably with the year-ago earnings of $3.16. | ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report GAMCO INVESTORS (GBL): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition will enable BlackRock to acquire MGPA's assets under management w... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report GAMCO INVESTORS (GBL): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition will enable BlackRock to acquire MGPA's assets under management w... | The acquisition will enable BlackRock to acquire MGPA's assets under management worth approximately $12 billion. ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report GAMCO INVESTORS (GBL): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report To read this a... |
21,911 | 2013-05-13 00:00:00 UTC | Ameriprise Hits New 52-Week High - Analyst Blog | AB | https://www.nasdaq.com/articles/ameriprise-hits-new-52-week-high-analyst-blog-2013-05-13 | null | null | Shares of Ameriprise Financial, Inc . ( AMP ) hit a new 52-week high, touching $78.25 almost at the end of the trading session on May 10, 2013. The closing price of this financial holding company represents a solid year-to-date return of 21.5%. The average trading volume over the last 3 months was 1.5 million shares.
D... | Other stocks that are also worth considering include AllianceBernstein Holding L.P. ( AB ), Invesco Ltd. ( IVZ ) and Waddell & Reed Financial Inc. ( WDR ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report WADDELL&REED -A (WD... | Other stocks that are also worth considering include AllianceBernstein Holding L.P. ( AB ), Invesco Ltd. ( IVZ ) and Waddell & Reed Financial Inc. ( WDR ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report WADDELL&REED -A (WD... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report WADDELL&REED -A (WDR): Free Stock Analysis Report To read this article on Zacks.com click here. Other stocks that are also worth considering include AllianceBernstein Holding ... | Other stocks that are also worth considering include AllianceBernstein Holding L.P. ( AB ), Invesco Ltd. ( IVZ ) and Waddell & Reed Financial Inc. ( WDR ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report WADDELL&REED -A (WD... |
21,912 | 2013-05-13 00:00:00 UTC | Legg Mason's AUM Declines in April - Analyst Blog | AB | https://www.nasdaq.com/articles/legg-masons-aum-declines-in-april-analyst-blog-2013-05-13 | null | null | Baltimore-based Legg Mason Inc. ( LM ) reported a dip in its assets under management (AUM) as of Apr 30, 2013, compared with the prior month, reflecting the liquidity redemption from a sovereign client. Preliminary month-end AUM came in at $655.4 billion, down 1.4% from March-end. Equity and Fixed Income AUM were up in... | Liquid assets, which are convertible into cash, decreased about 11.9% to $121.3 billion. Some better performing asset managers include AllianceBernstein Holding L.P. ( AB ) with a Zacks Rank #1 (Strong Buy). ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report LEGG MASON INC (LM): Free Stock Analysis Report To read this article on Zacks.com click here. Liquid assets, which are convertible into cash, decreased about 11.9% to $121.3 b... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report LEGG MASON INC (LM): Free Stock Analysis Report To read this article on Zacks.com click here. Liquid assets, which are convertible into cash, decreased about 11.9% to $121.3 b... | Liquid assets, which are convertible into cash, decreased about 11.9% to $121.3 billion. Some better performing asset managers include AllianceBernstein Holding L.P. ( AB ) with a Zacks Rank #1 (Strong Buy). ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (... |
21,913 | 2013-05-09 00:00:00 UTC | Invesco Hits New 52-Week High - Analyst Blog | AB | https://www.nasdaq.com/articles/invesco-hits-new-52-week-high-analyst-blog-2013-05-09 | null | null | Shares of Invesco Ltd. ( IVZ ) achieved a new 52-week high, touching $33.03 almost at the end of the trading session on May 8. The closing price of this well-known asset manager reflects a solid year-to-date return of 23.2%. The trading volume for the session was 3.1 million shares.
Despite hitting its 52-week high, th... | As of Mar 31, 2013, AUM grew 6.0% sequentially to $729.3 billion, reflecting net market gains, partially offset by unfavorable foreign exchange rate changes. Other investment managers worth considering include AllianceBernstein Holding L.P. ( AB ), Waddell & Reed Financial Inc. ( WDR ) and Virtus Investment Partners, I... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report WADDELL&REED -A (WDR): Free Stock Analysis Report To read this article on Zacks.com click here. As of Mar 31, 2013, AUM grew 6.0% sequentially to $729.3 billion, reflecting n... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report WADDELL&REED -A (WDR): Free Stock Analysis Report To read this article on Zacks.com click here. As of Mar 31, 2013, AUM grew 6.0% sequentially to $729.3 billion, reflecting n... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report WADDELL&REED -A (WDR): Free Stock Analysis Report To read this article on Zacks.com click here. As of Mar 31, 2013, AUM grew 6.0% sequentially to $729.3 billion, reflecting n... |
21,914 | 2013-05-08 00:00:00 UTC | Alliance Capital Management Holding L.P. (AB) Ex-Dividend Date Scheduled for May 09, 2013 | AB | https://www.nasdaq.com/articles/alliance-capital-management-holding-lp-ab-ex-dividend-date-scheduled-may-09-2013-2013-05 | null | null | Alliance Capital Management Holding L.P. ( AB ) will begin trading ex-dividend on May 09, 2013. A cash dividend payment of $0.38 per share is scheduled to be paid on May 23, 2013. Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an -5% decreas... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. AB is a part of the Finance sector, which includes companies such as Franklin Resources, Inc. ( BEN ) and AMERIPRISE FINANCIAL SERVICES, INC. ( AMP ). Zacks Investment Research reports AB's forecasted earnings ... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Alliance Capital Management Holding L.P. ( AB ) will begin trading ex-divide... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of AB was $25.45, representing a -1.2% decrease from the 52 week high of $25.76 and a 122.47% increase over the 52 week low of $11.44. For more information on the declaratio... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. Alliance Capital Management Holding L.P. ( AB ) will begin trading ex-dividend on May 09, 2013. The previous trading day's last sale of AB was $25.45, representing a -1.2% decrease from the 52 week high of $25.... |
21,915 | 2013-05-08 00:00:00 UTC | Franklin Hits New 52-Week High - Analyst Blog | AB | https://www.nasdaq.com/articles/franklin-hits-new-52-week-high-analyst-blog-2013-05-08 | null | null | Franklin Hits New 52-Week High
Shares of Franklin Resources Inc. ( BEN ) achieved a new 52-week high, touching $158.96 in the second half of the trading session on May 7. The closing price of this well-know asset manager represents a solid year-to-date return of 22.4%. The trading volume for the session was 341,909 sha... | ( AB ) and Virtus Investment Partners, Inc. ( VRTS ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. Despite hitting its 52-w... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. ( AB ) and Virtus Investment Partners, Inc. ( VRTS ). Growth Drivers Impressiv... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. ( AB ) and Virtus Investment Partners, Inc. ( VRTS ). Growth Drivers Impressiv... | ( AB ) and Virtus Investment Partners, Inc. ( VRTS ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. Despite hitting its 52-w... |
21,916 | 2013-05-07 00:00:00 UTC | Legg Mason Hits New 52-Week High - Analyst Blog | AB | https://www.nasdaq.com/articles/legg-mason-hits-new-52-week-high-analyst-blog-2013-05-07 | null | null | Shares of Legg Mason Inc. ( LM ) achieved a new 52-week high, touching $32.96 in the beginning of the trading session on May 6. The closing price of this well-know asset manager represents a solid year-to-date return of 24.6%. The average trading volume over the last 3 months was 1.7 million shares.
Despite hitting its... | Some better performing investment managers include Invesco Ltd. ( IVZ ), AllianceBernstein Holding L.P. ( AB ) and Virtus Investment Partners, Inc. ( VRTS ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report LEGG MASON INC (LM): Free Stock Analysis Report VIRTUS INVESTMT (VR... | Some better performing investment managers include Invesco Ltd. ( IVZ ), AllianceBernstein Holding L.P. ( AB ) and Virtus Investment Partners, Inc. ( VRTS ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report LEGG MASON INC (LM): Free Stock Analysis Report VIRTUS INVESTMT (VR... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report LEGG MASON INC (LM): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better performing investment managers include Invesco Ltd. ( IVZ ), Allianc... | Some better performing investment managers include Invesco Ltd. ( IVZ ), AllianceBernstein Holding L.P. ( AB ) and Virtus Investment Partners, Inc. ( VRTS ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report LEGG MASON INC (LM): Free Stock Analysis Report VIRTUS INVESTMT (VR... |
21,917 | 2013-05-07 00:00:00 UTC | Zacks #1 Rank Additions for Tuesday - Tale of the Tape | AB | https://www.nasdaq.com/articles/zacks-1-rank-additions-for-tuesday-tale-of-the-tape-2013-05-07 | null | null | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
Alleghany Corp ( Y )
AllianceBernstein Holding LP ( AB )
Ameris Bancorp ( ABCB )
AMN Healthcare Services, Inc. ( AHS )
ARC RESOURCES LTD. ( AETUF )
View the entire Zacks #1 Rank List .
ALLIANCEBERNSTN (AB): Free Stock Analysis Report
AMERIS BANCORP... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Alleghany Corp ( Y ) AllianceBernstein Holding LP ( AB ) Ameris Bancorp ( ABCB ) AMN Healthcare Services, Inc. ( AHS ) ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIS BANCORP (ABCB): Free Stock Analysis Report ARC RESOURCES (AETUF): Get Fre... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Alleghany Corp ( Y ) AllianceBernstein Holding LP ( AB ) Ameris Bancorp ( ABCB ) AMN Healthcare Services, Inc. ( AHS ) ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIS BANCORP (ABCB): Free Stock Analysis Report ARC RESOURCES (AETUF): Get Fre... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIS BANCORP (ABCB): Free Stock Analysis Report ARC RESOURCES (AETUF): Get Free Report AMN HLTHCR SVCS (AHS): Free Stock Analysis Report ALLEGHANY CORP (Y): Free Stock Analysis Report To read this article on Zacks.com click here. Here are 5 stocks added to the Zacks #1... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Alleghany Corp ( Y ) AllianceBernstein Holding LP ( AB ) Ameris Bancorp ( ABCB ) AMN Healthcare Services, Inc. ( AHS ) ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIS BANCORP (ABCB): Free Stock Analysis Report ARC RESOURCES (AETUF): Get Fre... |
21,918 | 2013-04-11 00:00:00 UTC | Legg Mason's AUM Rises in March - Analyst Blog | AB | https://www.nasdaq.com/articles/legg-masons-aum-rises-in-march-analyst-blog-2013-04-11 | null | null | Baltimore-based Legg Mason Inc. ( LM ) reported a rise in its assets under management (AUM) as of Mar 31, 2013, compared with the prior quarter, reflecting the acquisition of Fauchier Partners. Preliminary quarter-end AUM came in at $664.6 billion, up 2.4% sequentially. Equity and liquidity AUM were up in the quarter u... | Legg Mason's equity AUM as of March-end jumped 11.2% sequentially to $161.8 billion while liquid assets, which are convertible into cash, increased about 1.0% to $137.7 billion. Among other asset managers, we are not confident of an earnings beat from AllianceBernstein Holding L.P. (AB) with an Earnings ESP of 0.00% an... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report LEGG MASON INC (LM): Free Stock Analysis Report To read this article on Zacks.com click here. Legg Mason's equity AUM as of March-end jumped 11.2% sequentially to $161.8 billi... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report LEGG MASON INC (LM): Free Stock Analysis Report To read this article on Zacks.com click here. Legg Mason's equity AUM as of March-end jumped 11.2% sequentially to $161.8 billi... | Legg Mason's equity AUM as of March-end jumped 11.2% sequentially to $161.8 billion while liquid assets, which are convertible into cash, increased about 1.0% to $137.7 billion. Among other asset managers, we are not confident of an earnings beat from AllianceBernstein Holding L.P. (AB) with an Earnings ESP of 0.00% an... |
21,919 | 2013-04-11 00:00:00 UTC | Zacks #1 Rank Additions for Thursday - Tale of the Tape | AB | https://www.nasdaq.com/articles/zacks-1-rank-additions-for-thursday-tale-of-the-tape-2013-04-11 | null | null | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
AllianceBernstein Holding L.P. ( AB )
American Capital Agency Corp. ( AGNC )
BNC Bancorp ( BNCN )
Catalyst Pharmaceutical Partners, Inc. ( CPRX )
Geospace Technologies Corp ( GEOS )
View the entire Zacks #1 Rank List .
ALLIANCEBERNSTN (AB): Free St... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: AllianceBernstein Holding L.P. ( AB ) American Capital Agency Corp. ( AGNC ) BNC Bancorp ( BNCN ) Catalyst Pharmaceutical Partners, Inc. ( CPRX ) Geospace Technologies Corp ( GEOS ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free St... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: AllianceBernstein Holding L.P. ( AB ) American Capital Agency Corp. ( AGNC ) BNC Bancorp ( BNCN ) Catalyst Pharmaceutical Partners, Inc. ( CPRX ) Geospace Technologies Corp ( GEOS ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free St... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: AllianceBernstein Holding L.P. ( AB ) American Capital Agency Corp. ( AGNC ) BNC Bancorp ( BNCN ) Catalyst Pharmaceutical Partners, Inc. ( CPRX ) Geospace Technologies Corp ( GEOS ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free St... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: AllianceBernstein Holding L.P. ( AB ) American Capital Agency Corp. ( AGNC ) BNC Bancorp ( BNCN ) Catalyst Pharmaceutical Partners, Inc. ( CPRX ) Geospace Technologies Corp ( GEOS ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free St... |
21,920 | 2013-04-11 00:00:00 UTC | Market Hits All-Time High: Just a Mirage? - Analyst Blog | AB | https://www.nasdaq.com/articles/market-hits-all-time-high%3A-just-a-mirage-analyst-blog-2013-04-11 | null | null | On Apr 10, 2013, the S&P 500 index reached its all-time high of 1589.07 breaking its previous record intra-day high of 1576.09 on Oct 11, 2007. Its market capitalization has also swelled from just $5.9 trillion in 2009 to nearly $14.0 trillion. Close on the heels of the S&P 500 ascendancy, almost all the major indices ... | Although the job additions were significantly lesser than expected, the more talked-about point in the report was the drop in the unemployment rate, which apparently appears positive and augurs well for the economy that is limping back to normalcy from the wounds of a deep recession. Favorable Stress Test Results The s... | Favorable Stress Test Results The stress test results, as revealed by the Federal Reserve in early March, showed that 17 of the top 18 banks in the country had the requisite wherewithal to withstand a crisis, simulated by severe conditions such as an unemployment rate of 12.1%, housing price decline of 20%, share price... | Favorable Stress Test Results The stress test results, as revealed by the Federal Reserve in early March, showed that 17 of the top 18 banks in the country had the requisite wherewithal to withstand a crisis, simulated by severe conditions such as an unemployment rate of 12.1%, housing price decline of 20%, share price... | Falling Unemployment The U.S. job market was also supposedly improving as according to the latest U.S. job report, unemployment rate decreased to 7.6% in March from 7.7% in February with about 88,000 jobs added in the market. Favorable Stress Test Results The stress test results, as revealed by the Federal Reserve in e... |
21,921 | 2013-04-11 00:00:00 UTC | PFG Hits New 52-Week High - Analyst Blog | AB | https://www.nasdaq.com/articles/pfg-hits-new-52-week-high-analyst-blog-2013-04-11 | null | null | On Apr 10, 2013, shares of Principal Financial Group Inc . ( PFG ) hit a 52-week of $34.88.
The investment manager has remained focused to grow inorganically. On Mar 4, Principal Global Investors, LLC, the investment arm of Principal Financial agreed to purchase 55% shares of Liongate Capital Management in an effort to... | On Mar 4, Principal Global Investors, LLC, the investment arm of Principal Financial agreed to purchase 55% shares of Liongate Capital Management in an effort to expand its alternative investment capabilities. Valuation for Principal Financial looks reasonable. The 1-year return from the stock is 18.8%, above S&P's ret... | ( AB ) and Apollo Global Management, LLC ( APO ) among others carry a Zacks Rank #1 (Strong Buy), while Ameriprise Financial Inc. ( AMP ) carries a Zacks Rank #2 (Buy). ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report APOLLO GLOBAL-A (APO): Free Stock Analysis Report PR... | On Mar 4, Principal Global Investors, LLC, the investment arm of Principal Financial agreed to purchase 55% shares of Liongate Capital Management in an effort to expand its alternative investment capabilities. ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report APOLLO GLOB... | On Mar 4, Principal Global Investors, LLC, the investment arm of Principal Financial agreed to purchase 55% shares of Liongate Capital Management in an effort to expand its alternative investment capabilities. Valuation for Principal Financial looks reasonable. The 1-year return from the stock is 18.8%, above S&P's ret... |
21,922 | 2013-04-08 00:00:00 UTC | Unemployment and Home Prices: Real Relief? - Analyst Blog | AB | https://www.nasdaq.com/articles/unemployment-and-home-prices%3A-real-relief-analyst-blog-2013-04-08 | null | null | According to the latest U.S. job report, the unemployment rate decreased to 7.6% in March from 7.7% in February with about 88,000 jobs added to the market. Although the job additions were significantly less than expected, the takeway from the report was the drop in the unemployment rate, which apparently appears positi... | Since reaching its zenith at 67.3% in 2000, the labor participation rate has declined over the years as discouraged and frustrated Americans left the job market only to return when conditions briefly improved. According to the latest U.S. job report, the unemployment rate decreased to 7.6% in March from 7.7% in Februar... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report AFFIL MANAGERS (AMG): Free Stock Analysis Report BLACKSTONE GRP (BX): Free Stock Analysis Report KKR & CO LP (KKR): Free Stock Analysis Report To read this article on Zacks.com click here. According to the latest U.S. job report, the unemployment rate decreased to 7.6% i... | However, a critical analysis would reveal that the dip in the unemployment was primarily attributable to 500,000 Americans dropping out of the labor force, which dragged the labor participation rate (the percentage of the population within the demographic age of 16 and over in the labor force) to a 34-year low of 63.3%... | According to the latest U.S. job report, the unemployment rate decreased to 7.6% in March from 7.7% in February with about 88,000 jobs added to the market. However, the gradual retirement of an aging Baby Boomer population and a recession in late 2007 has continuously pegged back the labor participation rate. However, ... |
21,923 | 2013-03-18 00:00:00 UTC | Credit Suisse Settles Lawsuits - Analyst Blog | AB | https://www.nasdaq.com/articles/credit-suisse-settles-lawsuits-analyst-blog-2013-03-18 | null | null | According to Reuters , Credit Suisse Group AG ( CS ) agreed upon a settlement over charges levied against it by bond investors in National Century Financial Enterprises in lawsuits filed in the U.S. District Court, Southern District of New York. The note holders have accused the bank of raising money for the healthcare... | The Allegations The lodged complaint claims that Credit Suisse helped sell the notes issued by National Century and concealed the risks associated with the bonds, including the ability of the borrowers to repay. Therefore, the state of Arizona, AllianceBernstein Holding LP ( AB ), Lloyds TSB Bank Plc, MetLife Inc. ( ME... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report CREDIT SUISSE (CS): Free Stock Analysis Report METLIFE INC (MET): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the settlement of the lawsuits follows the dismissal of the bank's bid to... | Therefore, the state of Arizona, AllianceBernstein Holding LP ( AB ), Lloyds TSB Bank Plc, MetLife Inc. ( MET ), Allianz SE's investment management group, Pimco and other investors which purchased National Century bonds from 1998 to 2002, sued Credit Suisse on grounds of scam and conspiracy and filed the lawsuits. ALLI... | Notably, the settlement of the lawsuits follows the dismissal of the bank's bid to be tried in a separate hearing from convicted National Century's co-founder Lance Poulsen in Jan 2013. The Allegations The lodged complaint claims that Credit Suisse helped sell the notes issued by National Century and concealed the risk... |
21,924 | 2013-03-05 00:00:00 UTC | FINRA Fines Ameriprise & Affiliate - Analyst Blog | AB | https://www.nasdaq.com/articles/finra-fines-ameriprise-affiliate-analyst-blog-2013-03-05 | null | null | The Financial Industry Regulatory Authority (FINRA) has penalized Ameriprise Financial Inc. ( AMP ) and it's clearing firm, American Enterprise Investment Services Inc., (AEIS) for $750,000. The company and its affiliate were penalized on the grounds of failure to properly oversee wire-transfer requests and the transfe... | Further, absence of strict policies for detection and prevention of multiple fund transfers to third-party accounts gave a wide berth to fraudulent activities. ( AB ), Cohen & Steers Inc. ( CNS ) and Lazard Ltd. ( LAZ ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report ... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report COHEN&STRS INC (CNS): Free Stock Analysis Report LAZARD LTD (LAZ): Free Stock Analysis Report To read this article on Zacks.com click here. Further, absence of strict policies for detection and prevention of multiple fund... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report COHEN&STRS INC (CNS): Free Stock Analysis Report LAZARD LTD (LAZ): Free Stock Analysis Report To read this article on Zacks.com click here. Further, absence of strict policies for detection and prevention of multiple fund... | Further, absence of strict policies for detection and prevention of multiple fund transfers to third-party accounts gave a wide berth to fraudulent activities. ( AB ), Cohen & Steers Inc. ( CNS ) and Lazard Ltd. ( LAZ ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report ... |
21,925 | 2013-02-26 00:00:00 UTC | BlackRock Reiterated at Neutral - Analyst Blog | AB | https://www.nasdaq.com/articles/blackrock-reiterated-at-neutral-analyst-blog-2013-02-26 | null | null | On Feb 26, 2013, we reaffirmed our long-term recommendation on BlackRock, Inc. ( BLK ) at Neutral. This reflects the company's strong fourth-quarter results, which exceeded the Zacks Consensus Estimate by nearly 6%.
Why Neutral?
BlackRock's fourth-quarter adjusted earnings came in at $3.96 per share, significantly surp... | Other Investment Management Stocks Worth Considering While we prefer BlackRock, other financial investment management stocks worth a look include AllianceBernstein Holding L.P. ( AB ), Lazard Ltd. ( LAZ ) and Virtus Investment Partners, Inc. ( VRTS ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK)... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report LAZARD LTD (LAZ): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. Other Investment Management Stocks Worth Considering While we prefer BlackRock, o... | Other Investment Management Stocks Worth Considering While we prefer BlackRock, other financial investment management stocks worth a look include AllianceBernstein Holding L.P. ( AB ), Lazard Ltd. ( LAZ ) and Virtus Investment Partners, Inc. ( VRTS ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK)... | Other Investment Management Stocks Worth Considering While we prefer BlackRock, other financial investment management stocks worth a look include AllianceBernstein Holding L.P. ( AB ), Lazard Ltd. ( LAZ ) and Virtus Investment Partners, Inc. ( VRTS ). ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKROCK INC (BLK)... |
21,926 | 2013-02-19 00:00:00 UTC | Brookfield Beats, Raises Dividend - Analyst Blog | AB | https://www.nasdaq.com/articles/brookfield-beats-raises-dividend-analyst-blog-2013-02-19 | null | null | Brookfield Asset Management Inc. 's ( BAM ) fourth-quarter earnings per share came in at 72 cents, which significantly outpaced the Zacks Consensus Estimate of 30 cents. Yet, this was 16.3% below the earnings of 86 cents recorded in the year-ago quarter.
Better-than-expected quarterly results were aided by a solid top-... | However, other asset mangers like AllianceBernstein Holding L.P. ( AB ), Lazard Ltd. ( LAZ ) and Virtus Investment Partners, Inc. ( VRTS ) carry a Zacks Rank #1 (Strong Buy) and are worth considering. ALLIANCEBERNSTN (AB): Free Stock Analysis Report BROOKFIELD ASST (BAM): Free Stock Analysis Report LAZARD LTD (LAZ): Fr... | However, other asset mangers like AllianceBernstein Holding L.P. ( AB ), Lazard Ltd. ( LAZ ) and Virtus Investment Partners, Inc. ( VRTS ) carry a Zacks Rank #1 (Strong Buy) and are worth considering. ALLIANCEBERNSTN (AB): Free Stock Analysis Report BROOKFIELD ASST (BAM): Free Stock Analysis Report LAZARD LTD (LAZ): Fr... | However, other asset mangers like AllianceBernstein Holding L.P. ( AB ), Lazard Ltd. ( LAZ ) and Virtus Investment Partners, Inc. ( VRTS ) carry a Zacks Rank #1 (Strong Buy) and are worth considering. ALLIANCEBERNSTN (AB): Free Stock Analysis Report BROOKFIELD ASST (BAM): Free Stock Analysis Report LAZARD LTD (LAZ): Fr... | However, other asset mangers like AllianceBernstein Holding L.P. ( AB ), Lazard Ltd. ( LAZ ) and Virtus Investment Partners, Inc. ( VRTS ) carry a Zacks Rank #1 (Strong Buy) and are worth considering. ALLIANCEBERNSTN (AB): Free Stock Analysis Report BROOKFIELD ASST (BAM): Free Stock Analysis Report LAZARD LTD (LAZ): Fr... |
21,927 | 2013-02-15 00:00:00 UTC | Alliance Capital Management Holding L.P. (AB) Ex-Dividend Date Scheduled for February 20, 2013 | AB | https://www.nasdaq.com/articles/alliance-capital-management-holding-lp-ab-ex-dividend-date-scheduled-february-20-2013-2013 | null | null | Alliance Capital Management Holding L.P. ( AB ) will begin trading ex-dividend on February 20, 2013. A cash dividend payment of $0.4 per share is scheduled to be paid on March 14, 2013. Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 11.11... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. AB is a part of the Finance sector, which includes companies such as Franklin Resources, Inc. ( BEN ) and AMERIPRISE FINANCIAL SERVICES, INC. ( AMP ). Zacks Investment Research reports AB's forecasted earnings ... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Alliance Capital Management Holding L.P. ( AB ) will begin trading ex-divide... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of AB was $20.97, representing a -4.42% decrease from the 52 week high of $21.94 and a 83.3% increase over the 52 week low of $11.44. For more information on the declaration... | Shareholders who purchased AB stock prior to the ex-dividend date are eligible for the cash dividend payment. Alliance Capital Management Holding L.P. ( AB ) will begin trading ex-dividend on February 20, 2013. The previous trading day's last sale of AB was $20.97, representing a -4.42% decrease from the 52 week high o... |
21,928 | 2013-02-15 00:00:00 UTC | Zacks Rank #1 Addition for Friday - Tale of the Tape | AB | https://www.nasdaq.com/articles/zacks-rank-1-addition-for-friday-tale-of-the-tape-2013-02-15 | null | null | Here are 5 stocks added to the Zacks Rank #1 ("strong buy") List today:
Adobe Systems Inc. ( ADBE )
Advanced Semiconductor Engineering (ADR) ( ASX )
AG Mortgage Investment Trust Inc. ( MITT )
Air Lease Corp. ( AL )
AllianceBernstein Holding LP ( AB )
View the entire Zacks Rank #1 List .
ALLIANCEBERNSTN (AB): Free Stock... | Here are 5 stocks added to the Zacks Rank #1 ("strong buy") List today: Adobe Systems Inc. ( ADBE ) Advanced Semiconductor Engineering (ADR) ( ASX ) AG Mortgage Investment Trust Inc. ( MITT ) Air Lease Corp. ( AL ) AllianceBernstein Holding LP ( AB ) View the entire Zacks Rank #1 List . ALLIANCEBERNSTN (AB): Free Stock... | Here are 5 stocks added to the Zacks Rank #1 ("strong buy") List today: Adobe Systems Inc. ( ADBE ) Advanced Semiconductor Engineering (ADR) ( ASX ) AG Mortgage Investment Trust Inc. ( MITT ) Air Lease Corp. ( AL ) AllianceBernstein Holding LP ( AB ) View the entire Zacks Rank #1 List . ALLIANCEBERNSTN (AB): Free Stock... | Here are 5 stocks added to the Zacks Rank #1 ("strong buy") List today: Adobe Systems Inc. ( ADBE ) Advanced Semiconductor Engineering (ADR) ( ASX ) AG Mortgage Investment Trust Inc. ( MITT ) Air Lease Corp. ( AL ) AllianceBernstein Holding LP ( AB ) View the entire Zacks Rank #1 List . ALLIANCEBERNSTN (AB): Free Stock... | Here are 5 stocks added to the Zacks Rank #1 ("strong buy") List today: Adobe Systems Inc. ( ADBE ) Advanced Semiconductor Engineering (ADR) ( ASX ) AG Mortgage Investment Trust Inc. ( MITT ) Air Lease Corp. ( AL ) AllianceBernstein Holding LP ( AB ) View the entire Zacks Rank #1 List . ALLIANCEBERNSTN (AB): Free Stock... |
21,929 | 2013-01-14 00:00:00 UTC | Blackstone Lifted to Outperform - Analyst Blog | AB | https://www.nasdaq.com/articles/blackstone-lifted-to-outperform-analyst-blog-2013-01-14 | null | null | On January 9, 2013, we upgraded The Blackstone Group LP ( BX ) to Outperform based on this asset manager's strong fund raising ability and sound expansion activities.
Why the Upgrade?
Over the last 90 days, the Zacks Consensus Estimate for 2012 has increased nearly 11.0%. In addition, the company has delivered three po... | On January 9, 2013, we upgraded The Blackstone Group LP ( BX ) to Outperform based on this asset manager's strong fund raising ability and sound expansion activities. Further, Blackstone's robust expansion initiatives (organic and inorganic), powerful asset under management growth, solid fund raising ability and capita... | Further, Blackstone's robust expansion initiatives (organic and inorganic), powerful asset under management growth, solid fund raising ability and capital deployment actions were among the positives. ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKSTONE GRP (BX): Free Stock Analysis Report VIRTUS INVESTMT (VRTS):... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report BLACKSTONE GRP (BX): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. On January 9, 2013, we upgraded The Blackstone Group LP ( BX ) to Outperform based on this asset manager's strong fund raising... | On January 9, 2013, we upgraded The Blackstone Group LP ( BX ) to Outperform based on this asset manager's strong fund raising ability and sound expansion activities. Further, Blackstone's robust expansion initiatives (organic and inorganic), powerful asset under management growth, solid fund raising ability and capita... |
21,930 | 2013-01-14 00:00:00 UTC | Ameriprise Reiterated at Neutral - Analyst Blog | AB | https://www.nasdaq.com/articles/ameriprise-reiterated-at-neutral-analyst-blog-2013-01-14 | null | null | On January 9, 2013, we reaffirmed our long-term Neutral recommendation on Ameriprise Financial Inc. ( AMP ) based on its consistent assets under management (AUM) growth and robust capital deployment actions. However, elevated expenses and unsettling macro-economic factors are expected to remain a drag on its profitabil... | However, elevated expenses and unsettling macro-economic factors are expected to remain a drag on its profitability in the near to medium term. The recent and most notable acquisition is the asset management business of Columbia Management from Bank of America Corporation ( BAC ) in 2010. Other Stocks to Consider The o... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. However, elevated expenses and unsettling macro-economic factors are expec... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMERIPRISE FINL (AMP): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report VIRTUS INVESTMT (VRTS): Free Stock Analysis Report To read this article on Zacks.com click here. However, elevated expenses and unsettling macro-economic factors are expec... | The recent and most notable acquisition is the asset management business of Columbia Management from Bank of America Corporation ( BAC ) in 2010. However, elevated expenses and unsettling macro-economic factors are expected to remain a drag on its profitability in the near to medium term. Other Stocks to Consider The o... |
21,931 | 2013-01-09 00:00:00 UTC | HSBC's China Deal in Trouble - Analyst Blog | AB | https://www.nasdaq.com/articles/hsbcs-china-deal-in-trouble-analyst-blog-2013-01-09 | null | null | HSBC Holdings plc 's ( HBC ) divestiture of its entire stake (15.6%) in Chinese insurance giant Ping An Insurance (Group) Company of China, Ltd to Thailand-based Charoen Pokphand Group has come to an unexpected halt after China Development Bank (CDB) expressed concerns regarding the funding for the deal.
In December 20... | The problematic financing of the deal has prompted CDB to reconsider its decision of financing the deal, leading to an abrupt halt. The reshuffle involves streamlining its worldwide operations by shedding non-core assets to boost profitability. However, other stocks in the financial sector that are performing well and ... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report HSBC HOLDINGS (HBC): Free Stock Analysis Report HEARTLAND FINCL (HTLF): Free Stock Analysis Report To read this article on Zacks.com click here. The problematic financing of the deal has prompted CDB to reconsider its decision of financing the deal, leading to an abrupt ... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report HSBC HOLDINGS (HBC): Free Stock Analysis Report HEARTLAND FINCL (HTLF): Free Stock Analysis Report To read this article on Zacks.com click here. The problematic financing of the deal has prompted CDB to reconsider its decision of financing the deal, leading to an abrupt ... | The problematic financing of the deal has prompted CDB to reconsider its decision of financing the deal, leading to an abrupt halt. The reshuffle involves streamlining its worldwide operations by shedding non-core assets to boost profitability. However, other stocks in the financial sector that are performing well and ... |
21,932 | 2013-01-08 00:00:00 UTC | Neutral Stance on Waddell & Reed - Analyst Blog | AB | https://www.nasdaq.com/articles/neutral-stance-on-waddell-reed-analyst-blog-2013-01-08 | null | null | On December 31, 2012, we reiterated our long-term Neutral recommendation on Waddell & Reed Financial Inc. ( WDR ) based on the company's constantly improving assets under management (AUM) and robust capital deployment activities. However, the presence of substantial intangibles on its balance sheet and downward pressur... | There were continued strong investment performances behind the solid AUM growth trajectory despite unfavorable market conditions. Other stocks to consider The other stocks in the bank sector that are performing well and are worth considering include AllianceBernstein Holding L.P. ( AB ) and Heartland Financial USA Inc.... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report HEARTLAND FINCL (HTLF): Free Stock Analysis Report WADDELL&REED -A (WDR): Free Stock Analysis Report To read this article on Zacks.com click here. There were continued strong investment performances behind the solid AUM growth trajectory despite unfavorable market condit... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report HEARTLAND FINCL (HTLF): Free Stock Analysis Report WADDELL&REED -A (WDR): Free Stock Analysis Report To read this article on Zacks.com click here. There were continued strong investment performances behind the solid AUM growth trajectory despite unfavorable market condit... | There were continued strong investment performances behind the solid AUM growth trajectory despite unfavorable market conditions. Other stocks to consider The other stocks in the bank sector that are performing well and are worth considering include AllianceBernstein Holding L.P. ( AB ) and Heartland Financial USA Inc.... |
21,933 | 2013-01-08 00:00:00 UTC | AllianceBernstein Upped to Strong Buy - Analyst Blog | AB | https://www.nasdaq.com/articles/alliancebernstein-upped-to-strong-buy-analyst-blog-2013-01-08 | null | null | On January 5, Zacks Investment Research upgraded AllianceBernstein Holding L.P. ( AB ) to a Zacks #1 Rank (Strong Buy).
Why the Upgrade?
AllianceBernstein has been witnessing rising earnings estimates on the back of strong third-quarter 2012 results. Moreover, this well-known investment manager delivered positive earni... | Notably, the company's Distribution per unit came in at 36 cents, reflecting 38.0% increase over the prior-year quarter. On January 5, Zacks Investment Research upgraded AllianceBernstein Holding L.P. ( AB ) to a Zacks #1 Rank (Strong Buy). ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free St... | On January 5, Zacks Investment Research upgraded AllianceBernstein Holding L.P. ( AB ) to a Zacks #1 Rank (Strong Buy). ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report To read this article on Zacks.com click here. Notably... | On January 5, Zacks Investment Research upgraded AllianceBernstein Holding L.P. ( AB ) to a Zacks #1 Rank (Strong Buy). ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free Stock Analysis Report BLACKROCK INC (BLK): Free Stock Analysis Report To read this article on Zacks.com click here. Notably... | On January 5, Zacks Investment Research upgraded AllianceBernstein Holding L.P. ( AB ) to a Zacks #1 Rank (Strong Buy). Notably, the company's Distribution per unit came in at 36 cents, reflecting 38.0% increase over the prior-year quarter. ALLIANCEBERNSTN (AB): Free Stock Analysis Report FRANKLIN RESOUR (BEN): Free St... |
21,934 | 2013-01-07 00:00:00 UTC | Zacks #1 Rank Additions for Monday - Tale of the Tape | AB | https://www.nasdaq.com/articles/zacks-1-rank-additions-for-monday-tale-of-the-tape-2013-01-07 | null | null | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
Aeroflex Holding Corp. ( ARX )
AllianceBernstein Holding LP ( AB )
Atlas Energy LP ( ATLS )
Atmel Corp. ( ATML )
Big 5 Sporting Goods Corp. ( BGFV )
View the entire Zacks #1 Rank List .
ALLIANCEBERNSTN (AB): Free Stock Analysis Report
AEROFLEX HOLD... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Aeroflex Holding Corp. ( ARX ) AllianceBernstein Holding LP ( AB ) Atlas Energy LP ( ATLS ) Atmel Corp. ( ATML ) Big 5 Sporting Goods Corp. ( BGFV ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis Report AEROFLEX HOLD... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Aeroflex Holding Corp. ( ARX ) AllianceBernstein Holding LP ( AB ) Atlas Energy LP ( ATLS ) Atmel Corp. ( ATML ) Big 5 Sporting Goods Corp. ( BGFV ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis Report AEROFLEX HOLD... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Aeroflex Holding Corp. ( ARX ) AllianceBernstein Holding LP ( AB ) Atlas Energy LP ( ATLS ) Atmel Corp. ( ATML ) Big 5 Sporting Goods Corp. ( BGFV ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis Report AEROFLEX HOLD... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Aeroflex Holding Corp. ( ARX ) AllianceBernstein Holding LP ( AB ) Atlas Energy LP ( ATLS ) Atmel Corp. ( ATML ) Big 5 Sporting Goods Corp. ( BGFV ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis Report AEROFLEX HOLD... |
21,935 | 2012-12-07 00:00:00 UTC | Unisys Launched New Application - Analyst Blog | AB | https://www.nasdaq.com/articles/unisys-launched-new-application-analyst-blog-2012-12-07 | null | null | Unisys Corporation ( UIS ) recently unveiled its latest Agile Business (AB) Suite application software, Release 3.0, which can be used for Unisys ClearPath MCP and Microsoft Windows networks.
In today's world, there is a huge demand for creating and upgrading various mission-critical applications in an easier manner in... | Management stated that various organizations would now be able to improve its business productivity by leveraging the company's AB Suite Release 3.0. Unisys Corporation ( UIS ) recently unveiled its latest Agile Business (AB) Suite application software, Release 3.0, which can be used for Unisys ClearPath MCP and Micros... | Unisys Corporation ( UIS ) recently unveiled its latest Agile Business (AB) Suite application software, Release 3.0, which can be used for Unisys ClearPath MCP and Microsoft Windows networks. Moreover, as the company's AB Suite Release 3.0 is compatible with Enterprise Application Environment (EAE) process, it is easy ... | Moreover, as the company's AB Suite Release 3.0 is compatible with Enterprise Application Environment (EAE) process, it is easy to shift from EAE related applications to AB Suite Release 3.0 without affecting application performance. Unisys Corporation ( UIS ) recently unveiled its latest Agile Business (AB) Suite appl... | Unisys Corporation ( UIS ) recently unveiled its latest Agile Business (AB) Suite application software, Release 3.0, which can be used for Unisys ClearPath MCP and Microsoft Windows networks. Moreover, as the company's AB Suite Release 3.0 is compatible with Enterprise Application Environment (EAE) process, it is easy ... |
21,936 | 2012-11-27 00:00:00 UTC | AllianceBernstein Holding L.P. - Momentum | AB | https://www.nasdaq.com/articles/alliancebernstein-holding-l.p.-momentum-2012-11-27 | null | null | AllianceBernstein Holding L.P. ( AB ) posted impressive third quarter results late last month, which boosted 4 out of 5 total estimates for 2012 in the last 30 days. This Zacks #1 Rank (Strong Buy) global investment management firm has now surpassed the Zacks Consensus Estimate for three straight quarters. It also hit ... | AllianceBernstein Holding L.P. ( AB ) posted impressive third quarter results late last month, which boosted 4 out of 5 total estimates for 2012 in the last 30 days. Zacks' Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. The Zacks Consensus... | AllianceBernstein Holding L.P. ( AB ) posted impressive third quarter results late last month, which boosted 4 out of 5 total estimates for 2012 in the last 30 days. The Zacks Consensus Estimate for 2012 reflects year-over-year growth of about 6.8%, while the growth rate for 2013 is 15.2%. With a market cap of about $1... | AllianceBernstein Holding L.P. ( AB ) posted impressive third quarter results late last month, which boosted 4 out of 5 total estimates for 2012 in the last 30 days. The Zacks Consensus Estimate for 2012 reflects year-over-year growth of about 6.8%, while the growth rate for 2013 is 15.2%. With a market cap of about $1... | AllianceBernstein Holding L.P. ( AB ) posted impressive third quarter results late last month, which boosted 4 out of 5 total estimates for 2012 in the last 30 days. The Zacks Consensus Estimate for 2012 reflects year-over-year growth of about 6.8%, while the growth rate for 2013 is 15.2%. With a market cap of about $1... |
21,937 | 2012-10-09 00:00:00 UTC | Zacks #1 Rank Additions for Tuesday - Tale of the Tape | AB | https://www.nasdaq.com/articles/zacks-1-rank-additions-for-tuesday-tale-of-the-tape-2012-10-09 | null | null | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
Agrium Inc ( AGU )
AllianceBernstein Holding ( AB )
Amedisys Inc ( AMED )
American Woodmark ( AMWD )
BankFinancial Corp ( BFIN )
View the entire Zacks #1 Rank List .
ALLIANCEBERNSTN (AB): Free Stock Analysis Report
AGRIUM INC (AGU): Free Stock Anal... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Agrium Inc ( AGU ) AllianceBernstein Holding ( AB ) Amedisys Inc ( AMED ) American Woodmark ( AMWD ) BankFinancial Corp ( BFIN ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis Report AGRIUM INC (AGU): Free Stock Anal... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Agrium Inc ( AGU ) AllianceBernstein Holding ( AB ) Amedisys Inc ( AMED ) American Woodmark ( AMWD ) BankFinancial Corp ( BFIN ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis Report AGRIUM INC (AGU): Free Stock Anal... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report AGRIUM INC (AGU): Free Stock Analysis Report AMEDISYS INC (AMED): Free Stock Analysis Report AMER WOODMARK (AMWD): Free Stock Analysis Report BANKFINANCIAL (BFIN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed h... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Agrium Inc ( AGU ) AllianceBernstein Holding ( AB ) Amedisys Inc ( AMED ) American Woodmark ( AMWD ) BankFinancial Corp ( BFIN ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis Report AGRIUM INC (AGU): Free Stock Anal... |
21,938 | 2012-10-03 00:00:00 UTC | Zacks #1 Rank Additions for Wednesday - Tale of the Tape | AB | https://www.nasdaq.com/articles/zacks-1-rank-additions-for-wednesday-tale-of-the-tape-2012-10-03 | null | null | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
AllianceBernstein Holding LP ( AB )
The Allstate Corp. ( ALL )
American Science & Engineering, Inc. ( ASEI )
AMN Healthcare Services, Inc. ( AHS )
ArQule, Inc. ( ARQL )
View the entire Zacks #1 Rank List .
ALLIANCEBERNSTN (AB): Free Stock Analysis ... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: AllianceBernstein Holding LP ( AB ) The Allstate Corp. ( ALL ) American Science & Engineering, Inc. ( ASEI ) AMN Healthcare Services, Inc. ( AHS ) ArQule, Inc. ( ARQL ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis ... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: AllianceBernstein Holding LP ( AB ) The Allstate Corp. ( ALL ) American Science & Engineering, Inc. ( ASEI ) AMN Healthcare Services, Inc. ( AHS ) ArQule, Inc. ( ARQL ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis ... | ALLIANCEBERNSTN (AB): Free Stock Analysis Report AMN HLTHCR SVCS (AHS): Free Stock Analysis Report ALLSTATE CORP (ALL): Free Stock Analysis Report ARQULE INC (ARQL): Free Stock Analysis Report AMER SCI & ENG (ASEI): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expresse... | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: AllianceBernstein Holding LP ( AB ) The Allstate Corp. ( ALL ) American Science & Engineering, Inc. ( ASEI ) AMN Healthcare Services, Inc. ( AHS ) ArQule, Inc. ( ARQL ) View the entire Zacks #1 Rank List . ALLIANCEBERNSTN (AB): Free Stock Analysis ... |
21,939 | 2012-09-27 00:00:00 UTC | Investors Continue To Lighten Up On Equities As Market Rallies | AB | https://www.nasdaq.com/articles/investors-continue-lighten-equities-market-rallies-2012-09-27 | null | null | By Morningstar :
By Gregory Warren, CFA
While global equity markets have regained some of their footing during the third quarter, we don't believe this signals an end to market volatility. With Europe dealing with what has become an expanding debt crisis, most developed economies around the globe struggling to maintain... | In many ways, the story at American Funds mirrors those we've seen unfold at Legg Mason ( LM ) and AllianceBernstein ( AB ). Actively Managed Taxable Bond Fund Flows Back On Track Flows into actively managed taxable bond funds, which had been on a torrid pace during the first three months of 2012 (averaging around $22 ... | In many ways, the story at American Funds mirrors those we've seen unfold at Legg Mason ( LM ) and AllianceBernstein ( AB ). Actively Managed Taxable Bond Fund Flows Back On Track Flows into actively managed taxable bond funds, which had been on a torrid pace during the first three months of 2012 (averaging around $22 ... | Actively Managed Taxable Bond Fund Flows Back On Track Flows into actively managed taxable bond funds, which had been on a torrid pace during the first three months of 2012 (averaging around $22 billion a month), dropped off fairly significantly during the second quarter, with total inflows of $17 billion during April ... | Actively Managed Taxable Bond Fund Flows Back On Track Flows into actively managed taxable bond funds, which had been on a torrid pace during the first three months of 2012 (averaging around $22 billion a month), dropped off fairly significantly during the second quarter, with total inflows of $17 billion during April ... |
21,940 | 2012-08-01 00:00:00 UTC | Pre-Market Earnings Report for August 2, 2012 : APA, AEE, ANSS, ARIA, APO, ALE, AB, ABMD, AYR, AVD, ARQL, AGEN | AB | https://www.nasdaq.com/articles/pre-market-earnings-report-august-2-2012-apa-aee-anss-aria-apo-ale-ab-abmd-ayr-avd-arql | null | null | The following companies are expected to report earnings prior to market open on 08/02/2012. Visit our Earnings Calendar for a full list of expected earnings releases.
Apache Corporation ( APA ) is reporting for the quarter ending June 30, 2012. The oil (us exp & production) company's consensus earnings per share foreca... | Alliance Capital Management Holding L.P. ( AB ) is reporting for the quarter ending June 30, 2012. Zacks Investment Research reports that the 2012 Price to Earnings ratio for AB is 11.77 vs. an industry ratio of 16.50. ABIOMED, Inc. ( ABMD ) is reporting for the quarter ending June 30, 2012. | Alliance Capital Management Holding L.P. ( AB ) is reporting for the quarter ending June 30, 2012. Zacks Investment Research reports that the 2012 Price to Earnings ratio for AB is 11.77 vs. an industry ratio of 16.50. ABIOMED, Inc. ( ABMD ) is reporting for the quarter ending June 30, 2012. | Zacks Investment Research reports that the 2013 Price to Earnings ratio for ABMD is 102.50 vs. an industry ratio of 40.90, implying that they will have a higher earnings growth than their competitors in the same industry. Alliance Capital Management Holding L.P. ( AB ) is reporting for the quarter ending June 30, 2012.... | ABMD missed the consensus earnings per share in the 2nd calendar quarter by -120%. Alliance Capital Management Holding L.P. ( AB ) is reporting for the quarter ending June 30, 2012. Zacks Investment Research reports that the 2012 Price to Earnings ratio for AB is 11.77 vs. an industry ratio of 16.50. |
21,941 | 2012-07-03 00:00:00 UTC | Fitch Maintains Outlook on Invesco - Analyst Blog | AB | https://www.nasdaq.com/articles/fitch-maintains-outlook-on-invesco-analyst-blog-2012-07-03 | null | null | Fitch ratings have maintained its outlook on Invesco Ltd. ( IVZ ) at 'Stable' as a part of its review of four rated investment managers. Despite a decent first quarter 2012 results, the outlook remains unchanged as the agency is concerned about the impact of volatile equity markets on the company's financials.
Rational... | Despite a decent first quarter 2012 results, the outlook remains unchanged as the agency is concerned about the impact of volatile equity markets on the company's financials. Rationale for Stable Outlook Invesco reported a moderate quarterly performance along with continuous growth in assets under management as well as... | Conclusion Though the outlook and ratings remain unchanged, we remain cautious about Invesco's rising expenses that have the potential to dent its profitability in the upcoming quarters. ALLIANCEBERNSTN (AB): Free Stock Analysis Report AFFIL MANAGERS (AMG): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analy... | Fitch ratings have maintained its outlook on Invesco Ltd. ( IVZ ) at 'Stable' as a part of its review of four rated investment managers. ALLIANCEBERNSTN (AB): Free Stock Analysis Report AFFIL MANAGERS (AMG): Free Stock Analysis Report INVESCO LTD (IVZ): Free Stock Analysis Report To read this article on Zacks.com click... | Fitch ratings have maintained its outlook on Invesco Ltd. ( IVZ ) at 'Stable' as a part of its review of four rated investment managers. Conclusion Though the outlook and ratings remain unchanged, we remain cautious about Invesco's rising expenses that have the potential to dent its profitability in the upcoming quarte... |
21,942 | 2012-05-30 00:00:00 UTC | The Complete College Savings Solution | AB | https://www.nasdaq.com/articles/complete-college-savings-solution-2012-05-30 | null | null | With student loan debt gradually becoming what some believe will be the next major financial crisis, saving for college has never been more important. Yet, as if figuring out the best investments for a regular portfolio weren't hard enough, parents saving for college have to navigate an even more complex array of diffe... | Finally, simply keeping assets in a parent or grandparent's name retains maximum flexibility to invest and spend for expenses that might not otherwise qualify for favorable treatment in tax-favored college savings accounts. Some plans have fairly expensive investment options, as money managers AllianceBernstein ( AB ) ... | Some plans have fairly expensive investment options, as money managers AllianceBernstein ( AB ) , Franklin Resources ( BEN ) , and Hartford Financial ( HIG ) include actively managed options that charge much more than index-fund choices that other plans offer. Unlike 529 plans, Coverdell ESAs let you invest in just abo... | Some plans have fairly expensive investment options, as money managers AllianceBernstein ( AB ) , Franklin Resources ( BEN ) , and Hartford Financial ( HIG ) include actively managed options that charge much more than index-fund choices that other plans offer. Unlike 529 plans, Coverdell ESAs let you invest in just abo... | Some plans have fairly expensive investment options, as money managers AllianceBernstein ( AB ) , Franklin Resources ( BEN ) , and Hartford Financial ( HIG ) include actively managed options that charge much more than index-fund choices that other plans offer. Unlike 529 plans, Coverdell ESAs let you invest in just abo... |
21,943 | 2012-04-30 00:00:00 UTC | Can College Savings Be Saved? | AB | https://www.nasdaq.com/articles/can-college-savings-be-saved-2012-04-30 | null | null | Students are facing a crisis , as they struggle to afford the education they want and need. But while many focus on the impact of student-loan debt on young adults, few are looking at the other side of the coin -- namely, the incentives promoting college savings that in many cases aren't getting the job done.
The risin... | But in the ideal situation, students wouldn't have boatloads of debt to deal with because their parents would have been able to set aside enough money to cover their college educations. One vehicle that was established precisely to encourage college savings, the 529 plan , has seen some trouble attracting savings from ... | But in the ideal situation, students wouldn't have boatloads of debt to deal with because their parents would have been able to set aside enough money to cover their college educations. One vehicle that was established precisely to encourage college savings, the 529 plan , has seen some trouble attracting savings from ... | One vehicle that was established precisely to encourage college savings, the 529 plan , has seen some trouble attracting savings from some quarters -- and even some of the industry professionals that earn handsome incomes from such plans are starting to lose interest. With index-tracking exchange-traded funds charging ... | But in the ideal situation, students wouldn't have boatloads of debt to deal with because their parents would have been able to set aside enough money to cover their college educations. One vehicle that was established precisely to encourage college savings, the 529 plan , has seen some trouble attracting savings from ... |
21,944 | 2012-02-21 00:00:00 UTC | XL GROUP PLC (XL) - Profit Tracks | AB | https://www.nasdaq.com/articles/xl-group-plc-xl-profit-tracks-2012-02-21 | null | null | Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List - Stocks to Sell Now by 80% annually (+2% versus +10%). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.
Here is a synopsis of why AB a... | Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe: AllianceBernstein Holding LP ( AB ) announced fourth-quarter profit of 7 cents per share on February 10 that missed analysts? Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks; General Cable Cor... | Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks; General Cable Corporation?s ( BGC ) fourth-quarter profit of 30 cents per share, posted on February 8, lagged analysts? ALLIANCEBERNSTN ( AB ): Free Stock Analysis Report GENL CABLE CORP ( BGC ): Free Stock Analysis Report MEADWESTVACO CP (... | ALLIANCEBERNSTN ( AB ): Free Stock Analysis Report GENL CABLE CORP ( BGC ): Free Stock Analysis Report MEADWESTVACO CP ( MWV ): Free Stock Analysis Report XL GROUP PLC ( XL ): Free Stock Analysis Report To read this article on Zacks.com click here. Here is a synopsis of why AB and XL have a Zacks Rank of #5 (Strong Sel... | Here is a synopsis of why AB and XL have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe: AllianceBernstein Holding LP ( AB ) announced fourth-quarter profit of 7 ... |
21,945 | 2012-02-21 00:00:00 UTC | Zacks Sell List Highlights: AllianceBernstein Holding LP, XL Group plc, General Cable and MeadWestvaco - Press Releases | AB | https://www.nasdaq.com/articles/zacks-sell-list-highlights%3A-alliancebernstein-holding-lp-xl-group-plc-general-cable-and | null | null | For Immediate Release
Chicago, IL - February 21, 2012 - Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List - Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): AllianceBernstein Holding LP ( AB ) and XL Group plc ( XL ). Fur... | Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe: AllianceBernstein Holding LP ( AB ) announced fourth-quarter profit of 7 cents per share on February 10 that missed analysts' expectations by 66.67%. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by ... | These stocks are currently rated as a Zacks Rank #5 (Strong Sell): AllianceBernstein Holding LP ( AB ) and XL Group plc ( XL ). Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks; General Cable Corporation's ( BGC ) fourth-quarter profit of 30 cents per share, posted on February 8, lagged an... | 9339 support@zacks.com http://www.zacks.com ALLIANCEBERNSTN ( AB ): Free Stock Analysis Report GENL CABLE CORP ( BGC ): Free Stock Analysis Report MEADWESTVACO CP ( MWV ): Free Stock Analysis Report XL GROUP PLC ( XL ): Free Stock Analysis Report To read this article on Zacks.com click here. These stocks are currently ... | Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=94 About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): AllianceBernstein Holding LP ( AB ) and XL Group plc ( XL ). Fu... |
21,946 | 2011-10-11 00:00:00 UTC | How You Can Pass Today's Market Test | AB | https://www.nasdaq.com/articles/how-you-can-pass-todays-market-test-2011-10-11 | null | null | During good times, there's nothing more satisfying than investing in stocks and watching your portfolio value move steadily upward. But when turbulence hits, many investors reflexively head for the exits. Unfortunately for those who don't have much experience with investing, many financial companies make it easier rath... | After the market meltdown, insurance companies Prudential ( PRU ) , MetLife ( MET ) , and Lincoln Financial ( LNC ) all experienced big gains in variable annuity sales even as they implemented cost increases or reduced guaranteed benefits. Here are a couple of them: AllianceBernstein ( AB ) has added a feature that wil... | Here are a couple of them: AllianceBernstein ( AB ) has added a feature that will allow it to reduce risk levels of 529 investment portfolios whenever its managers expect periods of higher volatility. After the market meltdown, insurance companies Prudential ( PRU ) , MetLife ( MET ) , and Lincoln Financial ( LNC ) all... | Here are a couple of them: AllianceBernstein ( AB ) has added a feature that will allow it to reduce risk levels of 529 investment portfolios whenever its managers expect periods of higher volatility. After the market meltdown, insurance companies Prudential ( PRU ) , MetLife ( MET ) , and Lincoln Financial ( LNC ) all... | Here are a couple of them: AllianceBernstein ( AB ) has added a feature that will allow it to reduce risk levels of 529 investment portfolios whenever its managers expect periods of higher volatility. After the market meltdown, insurance companies Prudential ( PRU ) , MetLife ( MET ) , and Lincoln Financial ( LNC ) all... |
21,947 | 2010-04-26 00:00:00 UTC | Goldman Sparks Financial Stock Upgrades, Downgrades - BAC, BAM, WFC, UBS, CS, GS | AB | https://www.nasdaq.com/articles/goldman-sparks-financial-stock-upgrades-downgrades-bac-bam-wfc-ubs-cs-gs-2010-04-26-1 | null | null | In the wake of the Goldman Sachs ( GS ) bombshell, there have been a number of stock upgrades and stock downgrades to financial companies in the last week. GS stock was beaten down recently on news of a civil fraud investigation of Goldman by the SEC , and has sent shockwaves through the financial sector. Stock upgrade... | Directors Frank Bramble and Charles Holliday are the leading contenders to become Bank of America's new chairman when BAC stock announces its new leader, probably sometime this week. About Portfolio Grader: Every Sunday, renowned growth stock adviser Louis Navellier runs a fundamental analysis on the top 5,000 Wall Str... | All of these stock upgrades and downgrades are current as of April 26, 2010: Financial Stock Upgrades - Bank of America, Brookfield Asset, TD Ameritrade Financial stocks upgraded this week include Bank of America ( BAC ), Brookfield Asset Management ( BAM ), TD Ameritrade ( AMTD ), New York Community Bancorp ( NYB ), Z... | All of these stock upgrades and downgrades are current as of April 26, 2010: Financial Stock Upgrades - Bank of America, Brookfield Asset, TD Ameritrade Financial stocks upgraded this week include Bank of America ( BAC ), Brookfield Asset Management ( BAM ), TD Ameritrade ( AMTD ), New York Community Bancorp ( NYB ), Z... | Bank of America ( BAC ), a diversified financial services firm and one of the largest banks in the world, was upgraded to a C grade or a "hold" in Louis Navellier's database of stocks to buy and sell. Credit Suisse ( CS ) was downgraded from a C grade or "hold" to a D grade or "sell" in Louis Navellier's database of st... |
21,948 | 2023-12-16 04:00:00 UTC | AbbVie lawsuit says rival Adcentrx stole anti-cancer secrets | ABBV | https://www.nasdaq.com/articles/abbvie-lawsuit-says-rival-adcentrx-stole-anti-cancer-secrets | null | null | By Blake Brittain
Dec 18 (Reuters) - Pharmaceutical company AbbVie ABBV.N has sued startup Adcentrx Therapeutics in California federal court, accusing it of stealing trade secrets to develop competing cancer-fighting antibodies by hiring away an AbbVie scientist.
AbbVie said in the lawsuit, filed on Friday, that the "v... | By Blake Brittain Dec 18 (Reuters) - Pharmaceutical company AbbVie ABBV.N has sued startup Adcentrx Therapeutics in California federal court, accusing it of stealing trade secrets to develop competing cancer-fighting antibodies by hiring away an AbbVie scientist. AbbVie's lawsuit said that the North Chicago-based compa... | By Blake Brittain Dec 18 (Reuters) - Pharmaceutical company AbbVie ABBV.N has sued startup Adcentrx Therapeutics in California federal court, accusing it of stealing trade secrets to develop competing cancer-fighting antibodies by hiring away an AbbVie scientist. AbbVie said in the lawsuit, filed on Friday, that the "v... | By Blake Brittain Dec 18 (Reuters) - Pharmaceutical company AbbVie ABBV.N has sued startup Adcentrx Therapeutics in California federal court, accusing it of stealing trade secrets to develop competing cancer-fighting antibodies by hiring away an AbbVie scientist. AbbVie said in the lawsuit, filed on Friday, that the "v... | By Blake Brittain Dec 18 (Reuters) - Pharmaceutical company AbbVie ABBV.N has sued startup Adcentrx Therapeutics in California federal court, accusing it of stealing trade secrets to develop competing cancer-fighting antibodies by hiring away an AbbVie scientist. AbbVie said in the lawsuit, filed on Friday, that the "v... |
21,949 | 2023-12-16 00:00:00 UTC | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-proshares-sp-500-dividend-aristocrats-etf-nobl-a-strong-etf-right-now-9 | null | null | Launched on 10/09/2013, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta exchange traded fund offering broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the mar... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... |
21,950 | 2023-12-16 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-31 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
21,951 | 2023-12-16 00:00:00 UTC | Better Income Stock: AT&T or AbbVie? | ABBV | https://www.nasdaq.com/articles/better-income-stock%3A-att-or-abbvie | null | null | Dividend stocks can offer a valuable source of income for investors who want to diversify their portfolios. However, investors should also be aware that most of these stocks will gradually decline in value over time unless the dividend is reinvested.
This may seem surprising, but ample evidence supports this claim. Onl... | AbbVie's dividend yield is slightly higher than the average for its industry, and its stock is trading at a low valuation compared to its peers at less than 14 times forward earnings. Two of the most popular dividend stocks in the market today are AT&T (NYSE: T) and AbbVie (NYSE: ABBV), but they have different appeals.... | Two of the most popular dividend stocks in the market today are AT&T (NYSE: T) and AbbVie (NYSE: ABBV), but they have different appeals. AbbVie also has a decent yield of 4.02% and has established itself as a leading dividend growth stock and reliable passive income source for shareholders. The case for AbbVie AbbVie i... | AbbVie also has a decent yield of 4.02% and has established itself as a leading dividend growth stock and reliable passive income source for shareholders. AbbVie's dividend yield is slightly higher than the average for its industry, and its stock is trading at a low valuation compared to its peers at less than 14 times... | AbbVie also has a decent yield of 4.02% and has established itself as a leading dividend growth stock and reliable passive income source for shareholders. Two of the most popular dividend stocks in the market today are AT&T (NYSE: T) and AbbVie (NYSE: ABBV), but they have different appeals. The case for AbbVie AbbVie i... |
21,952 | 2023-12-16 00:00:00 UTC | 3 Biotech Stocks Most Wall Street Analysts Are Bullish About | ABBV | https://www.nasdaq.com/articles/3-biotech-stocks-most-wall-street-analysts-are-bullish-about | null | null | The scenario for the biotech industry in 2024 looks upbeat after a challenging ride in 2023. New drug approvals, pipeline development, and an increase in mergers & acquisitions (M&A) activity boosted investor sentiment in the last couple of months, even though an uncertain macroeconomic environment was a headwind.
Phar... | Pharma giant AbbVie ABBV recently announced two back-to-back acquisitions — Cerevel Therapeutics for $8.7 billion and ImmunoGen for $10.1 billion. Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Intra-Cellular Therapies I... | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Ph... | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Ph... | Pharma giant AbbVie ABBV recently announced two back-to-back acquisitions — Cerevel Therapeutics for $8.7 billion and ImmunoGen for $10.1 billion. Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Intra-Cellular Therapies I... |
21,953 | 2023-12-16 00:00:00 UTC | 3 of the Most Attractive Dividend Stocks in the Pharma Space | ABBV | https://www.nasdaq.com/articles/3-of-the-most-attractive-dividend-stocks-in-the-pharma-space | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In the realm of investment, pharma dividend stocks are a beacon for both stability and growth. This sector not only enhances the quality of life on a global scale but also presents lucrative opportunities for long-term investors.
Moreover, given the evergre... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com In the dynamic realm of pharmaceuticals, AbbVie (NYSE:ABBV) stands out with its strategic pivot away from Humira dependency. Moreover, AbbVie’s expansion into sectors like immunology, neuroscience, oncology, and aesthetics is paying off immensely. Therefore, A... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com In the dynamic realm of pharmaceuticals, AbbVie (NYSE:ABBV) stands out with its strategic pivot away from Humira dependency. Moreover, AbbVie’s expansion into sectors like immunology, neuroscience, oncology, and aesthetics is paying off immensely. Therefore, A... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com In the dynamic realm of pharmaceuticals, AbbVie (NYSE:ABBV) stands out with its strategic pivot away from Humira dependency. Moreover, AbbVie’s expansion into sectors like immunology, neuroscience, oncology, and aesthetics is paying off immensely. Therefore, A... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com In the dynamic realm of pharmaceuticals, AbbVie (NYSE:ABBV) stands out with its strategic pivot away from Humira dependency. Moreover, AbbVie’s expansion into sectors like immunology, neuroscience, oncology, and aesthetics is paying off immensely. Therefore, A... |
21,954 | 2023-12-14 00:00:00 UTC | 3 Fantastic Stocks That Could Enjoy a Santa Claus Rally | ABBV | https://www.nasdaq.com/articles/3-fantastic-stocks-that-could-enjoy-a-santa-claus-rally | null | null | You might think that the stock market would be really quiet during the holidays. After all, many investors are on vacation and take a break from buying and selling stocks. Interestingly, though, the S&P 500 often rises noticeably in the final five trading days of December and the first two days in January.
Three Motley... | Both transactions appear to be smart moves that will bolster AbbVie's pipeline and, in the case of ImmunoGen, add an approved cancer therapy with fast-growing sales to its lineup. Here's why they picked AbbVie (NYSE: ABBV), CRISPR Therapeutics (NASDAQ: CRSP), and Pfizer (NYSE: PFE). A rally has already begun for this s... | Here's why they picked AbbVie (NYSE: ABBV), CRISPR Therapeutics (NASDAQ: CRSP), and Pfizer (NYSE: PFE). A rally has already begun for this stock Keith Speights (AbbVie): We won't have to wait until after Christmas for one beaten-down stock to rally. The rally has already begun for AbbVie: Shares of the big drugmaker ha... | A rally has already begun for this stock Keith Speights (AbbVie): We won't have to wait until after Christmas for one beaten-down stock to rally. Here's why they picked AbbVie (NYSE: ABBV), CRISPR Therapeutics (NASDAQ: CRSP), and Pfizer (NYSE: PFE). The rally has already begun for AbbVie: Shares of the big drugmaker ha... | Here's why they picked AbbVie (NYSE: ABBV), CRISPR Therapeutics (NASDAQ: CRSP), and Pfizer (NYSE: PFE). A rally has already begun for this stock Keith Speights (AbbVie): We won't have to wait until after Christmas for one beaten-down stock to rally. The rally has already begun for AbbVie: Shares of the big drugmaker ha... |
21,955 | 2023-12-13 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-30 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
21,956 | 2023-12-12 00:00:00 UTC | Here's How Much You'd Have If You Invested $1000 in AbbVie a Decade Ago | ABBV | https://www.nasdaq.com/articles/heres-how-much-youd-have-if-you-invested-%241000-in-abbvie-a-decade-ago | null | null | How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants,... | AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics and eye care. What if you'd invested in AbbVie (ABBV) ten years ago? It may not have been easy to hold on to ABBV for all that time, but if you did, how much would your investment be worth to... | AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics and eye care. What if you'd invested in AbbVie (ABBV) ten years ago? It may not have been easy to hold on to ABBV for all that time, but if you did, how much would your investment be worth to... | So, if you had invested in AbbVie a decade ago, you're probably feeling pretty good about your investment today. What if you'd invested in AbbVie (ABBV) ten years ago? It may not have been easy to hold on to ABBV for all that time, but if you did, how much would your investment be worth today? | It may not have been easy to hold on to ABBV for all that time, but if you did, how much would your investment be worth today? AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica. What if you'd invested in AbbVie (ABBV) ten years ago? |
21,957 | 2023-12-12 00:00:00 UTC | US Consumer group seeks stronger warnings on Botox, similar treatments | ABBV | https://www.nasdaq.com/articles/us-consumer-group-seeks-stronger-warnings-on-botox-similar-treatments | null | null | By Leroy Leo
Dec 12 (Reuters) - Consumer advocacy group Public Citizen on Tuesday filed a petition with the U.S. Food and Drug Administration seeking to require makers of Botox and several similar injections to include stronger warnings about the risk of a potentially fatal muscle-paralyzing disease.
These injections, ... | The new petition seeks a stronger warning on the label of six toxin-based injections including market leader Botox from AbbVie ABBV.V, Revance Therapeutics' RVNC.O Daxxify, Evolus' EOLS.O Jeuveau, Supernus Pharmaceuticals' SUPN.O Myobloc, Galderma's Dysport and Xeomin from Merz Therapeutics. By Leroy Leo Dec 12 (Reuter... | The new petition seeks a stronger warning on the label of six toxin-based injections including market leader Botox from AbbVie ABBV.V, Revance Therapeutics' RVNC.O Daxxify, Evolus' EOLS.O Jeuveau, Supernus Pharmaceuticals' SUPN.O Myobloc, Galderma's Dysport and Xeomin from Merz Therapeutics. By Leroy Leo Dec 12 (Reuter... | The new petition seeks a stronger warning on the label of six toxin-based injections including market leader Botox from AbbVie ABBV.V, Revance Therapeutics' RVNC.O Daxxify, Evolus' EOLS.O Jeuveau, Supernus Pharmaceuticals' SUPN.O Myobloc, Galderma's Dysport and Xeomin from Merz Therapeutics. By Leroy Leo Dec 12 (Reuter... | The new petition seeks a stronger warning on the label of six toxin-based injections including market leader Botox from AbbVie ABBV.V, Revance Therapeutics' RVNC.O Daxxify, Evolus' EOLS.O Jeuveau, Supernus Pharmaceuticals' SUPN.O Myobloc, Galderma's Dysport and Xeomin from Merz Therapeutics. Public Citizen also asked t... |
21,958 | 2023-12-12 00:00:00 UTC | AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors | ABBV | https://www.nasdaq.com/articles/abbvie-just-followed-pfizers-big-move.-heres-what-it-means-for-investors | null | null | With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the pharma is intent on avoiding being left behind by the competition. Specifically, it's following in the footsteps of compa... | With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the pharma is intent on avoiding being left behind by the competition. If all goes according to plan, between the sales of El... | With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the pharma is intent on avoiding being left behind by the competition. If all goes according to plan, between the sales of El... | With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the pharma is intent on avoiding being left behind by the competition. In other words, ADCs are here to stay, and AbbVie's on... | If all goes according to plan, between the sales of Elahere, the expansion of its approved indications to include additional cancers, and the development of Immunogen's pipeline programs, AbbVie figures that its revenue could see boosted growth through roughly 2035. * They just revealed what they believe are the ten be... |
21,959 | 2023-12-11 00:00:00 UTC | Economic Safety Nets: 7 Defensive Stocks Providing Portfolio Stability | ABBV | https://www.nasdaq.com/articles/economic-safety-nets%3A-7-defensive-stocks-providing-portfolio-stability | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Although investors have some evidence of a possible economic recovery, they should still consider defensive stock picks. We just don’t know what will happen next. Moreover, certain data points contradict the optimistic narrative, thus warranting a reexamina... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com What it is: A biopharmaceutical company, AbbVie (NYSE:ABBV) develops and markets innovative medicines across various therapeutic areas. The company gained considerable awareness thanks to its buyout of Allergan, which gives AbbVie control of Botox. ABBV has be... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com What it is: A biopharmaceutical company, AbbVie (NYSE:ABBV) develops and markets innovative medicines across various therapeutic areas. The company gained considerable awareness thanks to its buyout of Allergan, which gives AbbVie control of Botox. ABBV has be... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com What it is: A biopharmaceutical company, AbbVie (NYSE:ABBV) develops and markets innovative medicines across various therapeutic areas. The company gained considerable awareness thanks to its buyout of Allergan, which gives AbbVie control of Botox. ABBV has be... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com What it is: A biopharmaceutical company, AbbVie (NYSE:ABBV) develops and markets innovative medicines across various therapeutic areas. The company gained considerable awareness thanks to its buyout of Allergan, which gives AbbVie control of Botox. ABBV has be... |
21,960 | 2023-12-11 00:00:00 UTC | Goldman Sachs Upgrades Abbvie (ABBV) | ABBV | https://www.nasdaq.com/articles/goldman-sachs-upgrades-abbvie-abbv | null | null | Fintel reports that on December 11, 2023, Goldman Sachs upgraded their outlook for Abbvie (NYSE:ABBV) from Neutral to Buy .
Analyst Price Forecast Suggests 15.97% Upside
As of November 27, 2023, the average one-year price target for Abbvie is 173.11. The forecasts range from a low of 136.35 to a high of $215.25. The av... | AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Fintel reports that on December 11, 2023, Goldman Sachs upgraded their outlook for Abbvie (NYSE:ABBV) from Neutral to Buy . Analyst Price Forecast Suggests 15.97% Upsid... | Fintel reports that on December 11, 2023, Goldman Sachs upgraded their outlook for Abbvie (NYSE:ABBV) from Neutral to Buy . Analyst Price Forecast Suggests 15.97% Upside As of November 27, 2023, the average one-year price target for Abbvie is 173.11. The projected annual revenue for Abbvie is 55,229MM, an increase of 0... | Fintel reports that on December 11, 2023, Goldman Sachs upgraded their outlook for Abbvie (NYSE:ABBV) from Neutral to Buy . Analyst Price Forecast Suggests 15.97% Upside As of November 27, 2023, the average one-year price target for Abbvie is 173.11. The projected annual revenue for Abbvie is 55,229MM, an increase of 0... | Analyst Price Forecast Suggests 15.97% Upside As of November 27, 2023, the average one-year price target for Abbvie is 173.11. Fintel reports that on December 11, 2023, Goldman Sachs upgraded their outlook for Abbvie (NYSE:ABBV) from Neutral to Buy . The projected annual revenue for Abbvie is 55,229MM, an increase of 0... |
21,961 | 2023-12-11 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-13 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
21,962 | 2023-12-11 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-29 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
21,963 | 2023-12-11 00:00:00 UTC | Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now | ABBV | https://www.nasdaq.com/articles/goldman-sachs-says-these-3-healthcare-giants-look-very-attractive-right-now | null | null | Barring some outliers, the US large cap pharmaceutical group has underperformed the broader markets this year.
In a setting characterized by formidable macro factors, such as economic growth trends and the trajectory of interest rates, Goldman Sachs’ Chris Shibutani says the group has shown it is “unstable on a defensi... | AbbVie, which is based in North Chicago, Illinois, sees high potential for these drugs going forward – and the company, in its last quarterly report, revised its full-year 2023 earnings outlook upward accordingly, setting expectations for adjusted diluted EPS this year in the range of $11.19 to $11.23. AbbVie, Inc. (AB... | AbbVie, which is based in North Chicago, Illinois, sees high potential for these drugs going forward – and the company, in its last quarterly report, revised its full-year 2023 earnings outlook upward accordingly, setting expectations for adjusted diluted EPS this year in the range of $11.19 to $11.23. AbbVie, Inc. (AB... | He writes, “As we exit 2023, ABBV’s delivery of more resilient than expected revenue performance for the Humira franchise in the face of multiple biosimilar entrants our confidence has increased in the potential for performance from growth products (Skyrizi, Rinvoq) and signature franchises (i.e., Botox) to generate an... | AbbVie, Inc. (ABBV) The second stock on our list of Goldman picks is AbbVie. According to Global Market Insights, it was thought to be worth $104 billion last year, and is expected to reach as high as $233.6 billion by 2032 – there is room here for both AbbVie and Merck to find customers. This puts AbbVie into direct c... |
21,964 | 2023-12-11 00:00:00 UTC | Health Rounds: New transplant approach may help more patients with sickle cell disease | ABBV | https://www.nasdaq.com/articles/health-rounds%3A-new-transplant-approach-may-help-more-patients-with-sickle-cell-disease | null | null | By Nancy Lapid
Dec 12 (Reuters) - Hello Health Rounds readers! Today we highlight two high profile studies presented at the ongoing American Society of Hematology (ASH) meeting in San Diego. The first involves a new bone marrow transplant approach that could help more patients with severe sickle cell disease. The other... | Drug combo improves mantle cell lymphoma outcomes In patients with relapsed or hard-to-control mantle cell lymphoma, a combination of two oral medications from AbbVie ABBV.N achieved an overall remission rate of 82% and prolonged the time until the disease got worse by about 10 months, researchers said on Tuesday at th... | Drug combo improves mantle cell lymphoma outcomes In patients with relapsed or hard-to-control mantle cell lymphoma, a combination of two oral medications from AbbVie ABBV.N achieved an overall remission rate of 82% and prolonged the time until the disease got worse by about 10 months, researchers said on Tuesday at th... | Drug combo improves mantle cell lymphoma outcomes In patients with relapsed or hard-to-control mantle cell lymphoma, a combination of two oral medications from AbbVie ABBV.N achieved an overall remission rate of 82% and prolonged the time until the disease got worse by about 10 months, researchers said on Tuesday at th... | Drug combo improves mantle cell lymphoma outcomes In patients with relapsed or hard-to-control mantle cell lymphoma, a combination of two oral medications from AbbVie ABBV.N achieved an overall remission rate of 82% and prolonged the time until the disease got worse by about 10 months, researchers said on Tuesday at th... |
21,965 | 2023-12-11 00:00:00 UTC | ABBV, NVO, or LLY: Which Healthcare Stock Could Generate the Highest Returns? | ABBV | https://www.nasdaq.com/articles/abbv-nvo-or-lly%3A-which-healthcare-stock-could-generate-the-highest-returns | null | null | Healthcare companies are not completely immune to macro pressures but are generally more resilient compared to companies in other sectors. This is because of the essential nature of medicines and services offered by healthcare companies. Moreover, several healthcare companies are developing various treatments to addres... | Using TipRanks’ Stock Comparison Tool, we placed AbbVie (NYSE:ABBV), Novo Nordisk (NYSE:NVO), and Eli Lilly (NYSE:LLY) against each other to find the healthcare stock that could fetch the most attractive returns as per Wall Street analysts. AbbVie (NYSE:ABBV) AbbVie investors have been worried about the impact of the l... | Using TipRanks’ Stock Comparison Tool, we placed AbbVie (NYSE:ABBV), Novo Nordisk (NYSE:NVO), and Eli Lilly (NYSE:LLY) against each other to find the healthcare stock that could fetch the most attractive returns as per Wall Street analysts. AbbVie (NYSE:ABBV) AbbVie investors have been worried about the impact of the l... | Using TipRanks’ Stock Comparison Tool, we placed AbbVie (NYSE:ABBV), Novo Nordisk (NYSE:NVO), and Eli Lilly (NYSE:LLY) against each other to find the healthcare stock that could fetch the most attractive returns as per Wall Street analysts. AbbVie (NYSE:ABBV) AbbVie investors have been worried about the impact of the l... | Using TipRanks’ Stock Comparison Tool, we placed AbbVie (NYSE:ABBV), Novo Nordisk (NYSE:NVO), and Eli Lilly (NYSE:LLY) against each other to find the healthcare stock that could fetch the most attractive returns as per Wall Street analysts. AbbVie (NYSE:ABBV) AbbVie investors have been worried about the impact of the l... |
21,966 | 2023-12-10 00:00:00 UTC | 4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December | ABBV | https://www.nasdaq.com/articles/4-top-dividend-stocks-yielding-more-than-4-to-buy-hand-over-fist-this-december | null | null | Many dividend stocks have sold off over the past year. Higher interest rates made lower-risk investments like bonds and bank CDs more attractive income-generating options. That weighed on the value of some high-quality dividend stocks, pushing up their yields.
On the bright side, income-seeking investors can lock in so... | The company's latest dividend increase "underscore[s] our confidence in AbbVie's long-term outlook," stated CEO Richard Gonzales in the third-quarter earnings release. The company's growth-focused investments should help drive its revenue higher over the long term, enabling AbbVie to continue increasing its attractive ... | Realty Income (NYSE: O), Brookfield Renewable (NYSE: BEPC)(NYSE: BEP), AbbVie (NYSE: ABBV), and Verizon (NYSE: VZ) all currently offer dividend yields above 4%, which is more than double the S&P 500's yield (1.5%). Great income investments to stock up on this month Realty Income, Brookfield Renewable, AbbVie, and Veriz... | Realty Income (NYSE: O), Brookfield Renewable (NYSE: BEPC)(NYSE: BEP), AbbVie (NYSE: ABBV), and Verizon (NYSE: VZ) all currently offer dividend yields above 4%, which is more than double the S&P 500's yield (1.5%). Great income investments to stock up on this month Realty Income, Brookfield Renewable, AbbVie, and Veriz... | The company's growth-focused investments should help drive its revenue higher over the long term, enabling AbbVie to continue increasing its attractive dividend. Great income investments to stock up on this month Realty Income, Brookfield Renewable, AbbVie, and Verizon pay very attractive dividends these days. Realty I... |
21,967 | 2023-12-10 00:00:00 UTC | AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? | ABBV | https://www.nasdaq.com/articles/abbvie-just-announced-2-big-acquisitions%3A-is-this-dividend-king-a-no-brainer-buy-right-now | null | null | Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days.
During 2023 investors have primarily focused on the company's declining revenue and profits, which stem from the loss of paten... | And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days. AbbVie's share price reflected the concerns. However, AbbVie just announced two big acquisitions, spurring its stock to rebound somewhat. | On Nov. 30, AbbVie announced its plans to acquire ImmunoGen (NASDAQ: IMGN) in an all-cash transaction valued at roughly $10.1 billion. Only seven days after announcing its acquisition of ImmunoGen, AbbVie revealed plans to also acquire Cerevel Therapeutics (NASDAQ: CERE). Before you buy stock in AbbVie, consider this: ... | How acquiring ImmunoGen and Cerevel will help AbbVie Acquiring ImmunoGen should make a quicker splash for AbbVie. I don't think the ImmunoGen and Cerevel acquisitions are obvious reasons to buy AbbVie stock right now. Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identif... | I don't think the ImmunoGen and Cerevel acquisitions are obvious reasons to buy AbbVie stock right now. Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and AbbVie wasn't one of them. And it's a... |
21,968 | 2023-12-10 00:00:00 UTC | The 3 Best Cheap Stocks to Buy in December | ABBV | https://www.nasdaq.com/articles/the-3-best-cheap-stocks-to-buy-in-december | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The rising market in 2023 has not lifted all boats. Some stocks look extremely cheap right now. This offers investors an opportunity to buy shares of great companies at distressed prices and ride them higher in coming months and years. While some stocks are... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Pharmaceutical giant AbbVie’s (NYSE:ABBV) stock looks cheap right now, having fallen 10% in 2023 and not far from its 52-week low. Also, ABBV is subject to competition from cheaper generic alternatives. AbbVie racked up $21 billion in sales during 2022 alone. | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Pharmaceutical giant AbbVie’s (NYSE:ABBV) stock looks cheap right now, having fallen 10% in 2023 and not far from its 52-week low. Also, ABBV is subject to competition from cheaper generic alternatives. AbbVie racked up $21 billion in sales during 2022 alone. | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Pharmaceutical giant AbbVie’s (NYSE:ABBV) stock looks cheap right now, having fallen 10% in 2023 and not far from its 52-week low. Also, ABBV is subject to competition from cheaper generic alternatives. AbbVie racked up $21 billion in sales during 2022 alone. | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Pharmaceutical giant AbbVie’s (NYSE:ABBV) stock looks cheap right now, having fallen 10% in 2023 and not far from its 52-week low. Also, ABBV is subject to competition from cheaper generic alternatives. AbbVie racked up $21 billion in sales during 2022 alone. |
21,969 | 2023-12-09 00:00:00 UTC | Better Dividend Stock: AbbVie vs. Medical Properties Trust | ABBV | https://www.nasdaq.com/articles/better-dividend-stock%3A-abbvie-vs.-medical-properties-trust | null | null | Income-seeking investors have some interesting options to choose from in the healthcare sector right now. AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past decade, and Medical Properties Trust (NYSE: MPW), a real estate investment trust (REIT) that focuses on hospitals, both offer di... | AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past decade, and Medical Properties Trust (NYSE: MPW), a real estate investment trust (REIT) that focuses on hospitals, both offer dividend yields that are way above average. The case for AbbVie AbbVie is a Dividend King that has raised it... | AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past decade, and Medical Properties Trust (NYSE: MPW), a real estate investment trust (REIT) that focuses on hospitals, both offer dividend yields that are way above average. The case for AbbVie AbbVie is a Dividend King that has raised it... | AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past decade, and Medical Properties Trust (NYSE: MPW), a real estate investment trust (REIT) that focuses on hospitals, both offer dividend yields that are way above average. Before you buy stock in AbbVie, consider this: The Motley Fool S... | AbbVie's lucrative drug sales generated $24.7 billion in free cash flow over the past year. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Abb... |
21,970 | 2023-12-08 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-28 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
21,971 | 2023-12-08 00:00:00 UTC | Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-abbv-to-buy-cere-jnjs-2024-view-lly-nvs-get-fda-nod | null | null | This week, AbbVie ABBV announced a definitive agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion. The FDA approved Novartis’ NVS rare blood disorder drug, Fabhalta (iptacopan) and Eli Lilly’s LLY Jaypirca for its second leukemia indication. J&J JNJ announced sales and earnings growth expe... | This week, AbbVie ABBV announced a definitive agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion. Recap of the Week’s Most Important Stories AbbVie to Buy Cerevel Therapeutics: AbbVie offered to buy Cerevel Therapeutics for $45 per share in cash, which adds up to a total equity value of ... | Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com clic... | Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com clic... | This week, AbbVie ABBV announced a definitive agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion. Recap of the Week’s Most Important Stories AbbVie to Buy Cerevel Therapeutics: AbbVie offered to buy Cerevel Therapeutics for $45 per share in cash, which adds up to a total equity value of ... |
21,972 | 2023-12-08 00:00:00 UTC | 3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows | ABBV | https://www.nasdaq.com/articles/3-high-yielding-dividend-stocks-that-are-near-their-52-week-lows-0 | null | null | Are you looking for some quality dividend stocks to buy right now? When it comes to investing, it's often a good idea to check out those that haven't been doing too well lately and are trading near their lows. If the businesses are in good shape, that can make for great buying opportunities because when stock prices ar... | Investors are feeling bearish on the stock since AbbVie's top-selling rheumatoid arthritis drug, Humira, has lost patent protection and its sales are down 29% this year amid rising competition. AbbVie also recently announced plans to acquire oncology company ImmunoGen for $10 billion, which makes antibody-drug conjugat... | Three dividend stocks that have underperformed the S&P 500 this year and are trading near their lows are AbbVie (NYSE: ABBV), ExxonMobil (NYSE: XOM), and Cisco Systems (NASDAQ: CSCO). AbbVie Pharmaceutical maker AbbVie is known for being a solid dividend stock. This year, however, hasn't been a great one for AbbVie wit... | Three dividend stocks that have underperformed the S&P 500 this year and are trading near their lows are AbbVie (NYSE: ABBV), ExxonMobil (NYSE: XOM), and Cisco Systems (NASDAQ: CSCO). AbbVie Pharmaceutical maker AbbVie is known for being a solid dividend stock. This year, however, hasn't been a great one for AbbVie wit... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! Three dividend stocks that have underperformed the S&P 500 this year and are trading near their lows are AbbVie (NYSE: ABBV), ExxonMobil (NYSE: XOM), and Cisco Systems (NASDAQ: CSCO). AbbVie P... |
21,973 | 2023-12-08 00:00:00 UTC | The Zacks Analyst Blog Highlights AbbVie, NIKE, BHP Group, CME Group and Block | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-abbvie-nike-bhp-group-cme-group-and-block | null | null | For Immediate Release
Chicago, IL – December 8, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, NIKE, In... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, NIKE, Inc. NKE, BHP Group Ltd. BHP, CME Group Inc. CME and Block, Inc. SQ. Here are highlights from Thursday’s Analyst Blog: Top Stock Reports for AbbVie, NIKE and BHP The Zacks Research Daily presents the best research output of our analyst team. Today's ... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, NIKE, Inc. NKE, BHP Group Ltd. BHP, CME Group Inc. CME and Block, Inc. SQ. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., NIKE, Inc. and BHP Group Ltd. Click to get this free report CME Group Inc. (CME) : Fr... | Here are highlights from Thursday’s Analyst Blog: Top Stock Reports for AbbVie, NIKE and BHP The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., NIKE, Inc. and BHP Group Ltd. Click to get this fre... | Here are highlights from Thursday’s Analyst Blog: Top Stock Reports for AbbVie, NIKE and BHP The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., NIKE, Inc. and BHP Group Ltd. Stocks recently featu... |
21,974 | 2023-12-08 00:00:00 UTC | AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? | ABBV | https://www.nasdaq.com/articles/abbvies-on-an-acquisition-binge.-could-your-favorite-biotech-stock-be-next | null | null | These days, it seems like biotech buyout offers are falling from the sky. During the week ended Dec. 6, AbbVie (NYSE: ABBV) announced not one but two big acquisitions.
The pharma giant's latest big buyout offer is for Cerevel Therapeutics (NASDAQ: CERE), a clinical-stage company developing treatments for schizophrenia ... | AbbVie's Humira had an incredible run, but billions in annual sales started evaporating in front of investors' eyes when lower-cost biosimilar versions launched in the U.S. earlier this year. During the week ended Dec. 6, AbbVie (NYSE: ABBV) announced not one but two big acquisitions. Despite not having any approved pr... | 12/6/23 AbbVie Cerevel Therapeutics Neurology Clinical $8.7 billion $45.00 22% 11/30/23 AbbVie ImmunoGen Oncology Commercial $10.1 billion $31.26 95% 10/3/23 Eli Lilly Point Biopharma Oncology Clinical $1.4 billion $12.50 87% 7/28/23 Biogen Reata Pharmaceuticals Neurology Commercial $7.3 billion $172.50 59% Data source... | 12/6/23 AbbVie Cerevel Therapeutics Neurology Clinical $8.7 billion $45.00 22% 11/30/23 AbbVie ImmunoGen Oncology Commercial $10.1 billion $31.26 95% 10/3/23 Eli Lilly Point Biopharma Oncology Clinical $1.4 billion $12.50 87% 7/28/23 Biogen Reata Pharmaceuticals Neurology Commercial $7.3 billion $172.50 59% Data source... | AbbVie's recent offers for Cerevel Therapeutics and ImmunoGen suggest another wave of acquisitions is just around the corner. During the week ended Dec. 6, AbbVie (NYSE: ABBV) announced not one but two big acquisitions. Despite not having any approved products to sell yet, AbbVie offered Cerevel $8.7 billion in cash, o... |
21,975 | 2023-12-07 00:00:00 UTC | Health Care Sector Update for 12/07/2023: ABBV, CERE, JNJ, MRK, LLY | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-12-07-2023%3A-abbv-cere-jnj-mrk-lly | null | null | Health care stocks fell Thursday afternoon with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.7%.
In corporate news, AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total eq... | In corporate news, AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total equity value of $8.7 billion, the drugmakers said in a joint statement late Wednesday. AbbVie shares rose 0.8%, and Cerevel jumped 12% in recent Thursday trading. The White House said it would use "m... | AbbVie shares rose 0.8%, and Cerevel jumped 12% in recent Thursday trading. In corporate news, AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total equity value of $8.7 billion, the drugmakers said in a joint statement late Wednesday. Health care stocks fell Thursday aft... | In corporate news, AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total equity value of $8.7 billion, the drugmakers said in a joint statement late Wednesday. AbbVie shares rose 0.8%, and Cerevel jumped 12% in recent Thursday trading. Health care stocks fell Thursday aft... | In corporate news, AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total equity value of $8.7 billion, the drugmakers said in a joint statement late Wednesday. AbbVie shares rose 0.8%, and Cerevel jumped 12% in recent Thursday trading. Health care stocks fell Thursday aft... |
21,976 | 2023-12-07 00:00:00 UTC | Healthcare Gems: 3 Essential Long-Term Stock Picks | ABBV | https://www.nasdaq.com/articles/healthcare-gems%3A-3-essential-long-term-stock-picks | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Healthcare stocks are a great way for investors to achieve long-term wealth creation. The healthcare sector is essential to solving some of the world’s most pressing issues from heart disease, Alzheimer’s, and cancer.
And to be sure, there are a number of ... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) is one of the largest pharmaceutical companies in the world. AbbVie’s stock has fallen 10% in 2023 due to sluggish sales and EPS growth. AbbVie raised their full year EPS guidance from $10.86 – $11.06 per share to $11.19 – $11.23 per share. | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) is one of the largest pharmaceutical companies in the world. AbbVie’s stock has fallen 10% in 2023 due to sluggish sales and EPS growth. AbbVie raised their full year EPS guidance from $10.86 – $11.06 per share to $11.19 – $11.23 per share. | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) is one of the largest pharmaceutical companies in the world. AbbVie’s stock has fallen 10% in 2023 due to sluggish sales and EPS growth. AbbVie raised their full year EPS guidance from $10.86 – $11.06 per share to $11.19 – $11.23 per share. | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) is one of the largest pharmaceutical companies in the world. AbbVie’s stock has fallen 10% in 2023 due to sluggish sales and EPS growth. AbbVie raised their full year EPS guidance from $10.86 – $11.06 per share to $11.19 – $11.23 per share. |
21,977 | 2023-12-07 00:00:00 UTC | Health Care Sector Update for 12/07/2023: WBA, ABBV, CERE, JNJ, MRK, LLY, SLDB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-12-07-2023%3A-wba-abbv-cere-jnj-mrk-lly-sldb | null | null | Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.7%.
In corporate news, Walgreens Boots Alliance (WBA) said Thursday it is offering expanded COVID-19 and flu testing and ... | AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total equity value of $8.7 billion, the drugmakers said in a joint statement late Wednesday. AbbVie shares rose 0.9%, and Cerevel jumped nearly 12% in recent Thursday trading. In corporate news, Walgreens Boots Alliance (WBA... | AbbVie shares rose 0.9%, and Cerevel jumped nearly 12% in recent Thursday trading. AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total equity value of $8.7 billion, the drugmakers said in a joint statement late Wednesday. Health care stocks fell late Thursday afternoon,... | AbbVie shares rose 0.9%, and Cerevel jumped nearly 12% in recent Thursday trading. AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total equity value of $8.7 billion, the drugmakers said in a joint statement late Wednesday. Health care stocks fell late Thursday afternoon,... | AbbVie shares rose 0.9%, and Cerevel jumped nearly 12% in recent Thursday trading. AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total equity value of $8.7 billion, the drugmakers said in a joint statement late Wednesday. Health care stocks fell late Thursday afternoon,... |
21,978 | 2023-12-07 00:00:00 UTC | AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say | ABBV | https://www.nasdaq.com/articles/abbvies-%248.7-bln-bet-on-cerevel-is-risky-but-smart-analysts-say | null | null | By Bhanvi Satija and Khushi Mandowara
Dec 7 (Reuters) - AbbVie's ABBV.N decision to buy Cerevel Therapeutics CERE.O before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said.
North Chicago, Illinois-based Abb... | By Bhanvi Satija and Khushi Mandowara Dec 7 (Reuters) - AbbVie's ABBV.N decision to buy Cerevel Therapeutics CERE.O before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said. North Chicago, Illinois-based Abb... | By Bhanvi Satija and Khushi Mandowara Dec 7 (Reuters) - AbbVie's ABBV.N decision to buy Cerevel Therapeutics CERE.O before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said. North Chicago, Illinois-based Abb... | By Bhanvi Satija and Khushi Mandowara Dec 7 (Reuters) - AbbVie's ABBV.N decision to buy Cerevel Therapeutics CERE.O before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said. "With this deal, however, AbbVie ... | By Bhanvi Satija and Khushi Mandowara Dec 7 (Reuters) - AbbVie's ABBV.N decision to buy Cerevel Therapeutics CERE.O before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said. North Chicago, Illinois-based Abb... |
21,979 | 2023-12-07 00:00:00 UTC | Bain scores over tenfold return with $8.7 billion Cerevel sale | ABBV | https://www.nasdaq.com/articles/bain-scores-over-tenfold-return-with-%248.7-billion-cerevel-sale | null | null | By Greg Roumeliotis
Dec 7 (Reuters) - Private equity firm Bain Capital stands to make more than 10 times the $250 million it invested in Cerevel Therapeutics Holdings Inc CERE.O following the neurology-focused drug developer's $8.7 billion sale to AbbVie Inc ABBV.N, according to regulatory filings.
Boston-based Bain co... | By Greg Roumeliotis Dec 7 (Reuters) - Private equity firm Bain Capital stands to make more than 10 times the $250 million it invested in Cerevel Therapeutics Holdings Inc CERE.O following the neurology-focused drug developer's $8.7 billion sale to AbbVie Inc ABBV.N, according to regulatory filings. The deal with AbbVie... | By Greg Roumeliotis Dec 7 (Reuters) - Private equity firm Bain Capital stands to make more than 10 times the $250 million it invested in Cerevel Therapeutics Holdings Inc CERE.O following the neurology-focused drug developer's $8.7 billion sale to AbbVie Inc ABBV.N, according to regulatory filings. EXCLUSIVE-AbbVie nea... | By Greg Roumeliotis Dec 7 (Reuters) - Private equity firm Bain Capital stands to make more than 10 times the $250 million it invested in Cerevel Therapeutics Holdings Inc CERE.O following the neurology-focused drug developer's $8.7 billion sale to AbbVie Inc ABBV.N, according to regulatory filings. EXCLUSIVE-AbbVie nea... | By Greg Roumeliotis Dec 7 (Reuters) - Private equity firm Bain Capital stands to make more than 10 times the $250 million it invested in Cerevel Therapeutics Holdings Inc CERE.O following the neurology-focused drug developer's $8.7 billion sale to AbbVie Inc ABBV.N, according to regulatory filings. The deal with AbbVie... |
21,980 | 2023-12-07 00:00:00 UTC | Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout | ABBV | https://www.nasdaq.com/articles/abbvie-to-focus-on-smaller-deals-after-cerevel-and-immunogen-buyout | null | null | Adds details from conference call and background throughout, analyst comment in paragraph 8
Dec 7 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cereve... | "I would not anticipate similar sized transactions for the foreseeable future," said AbbVie's Chief Operating Officer Robert Michael on a conference call, referring to the company's $8.7 billion buyout of Cerevel Therapeutics CERE.O announced on Wednesday. "With additions of Cerevel and ImmunoGen, AbbVie is in a strong... | "I would not anticipate similar sized transactions for the foreseeable future," said AbbVie's Chief Operating Officer Robert Michael on a conference call, referring to the company's $8.7 billion buyout of Cerevel Therapeutics CERE.O announced on Wednesday. "With additions of Cerevel and ImmunoGen, AbbVie is in a strong... | Adds details from conference call and background throughout, analyst comment in paragraph 8 Dec 7 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cereve... | Adds details from conference call and background throughout, analyst comment in paragraph 8 Dec 7 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cereve... |
21,981 | 2023-12-07 00:00:00 UTC | Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now. | ABBV | https://www.nasdaq.com/articles/looking-for-dividend-growth-in-the-new-year-3-magnificent-stocks-to-buy-now. | null | null | It's too early to predict what the market will do next year, but there's one way to guarantee some stock market gains. And that's by investing in dividend stocks.
These players offer you passive income -- even when their share prices are falling or the general market is declining. They represent returns you can count o... | I'm talking about healthcare giants AbbVie (NYSE: ABBV), Medtronic (NYSE: MDT), and Pfizer (NYSE: PFE). AbbVie AbbVie has made dividends its priority since its start, back in 2013 when it was spun off from Abbott Laboratories. AbbVie says that once earnings pick up, the company will further boost its dividend payments,... | I'm talking about healthcare giants AbbVie (NYSE: ABBV), Medtronic (NYSE: MDT), and Pfizer (NYSE: PFE). AbbVie AbbVie has made dividends its priority since its start, back in 2013 when it was spun off from Abbott Laboratories. AbbVie says that once earnings pick up, the company will further boost its dividend payments,... | I'm talking about healthcare giants AbbVie (NYSE: ABBV), Medtronic (NYSE: MDT), and Pfizer (NYSE: PFE). AbbVie AbbVie has made dividends its priority since its start, back in 2013 when it was spun off from Abbott Laboratories. AbbVie says that once earnings pick up, the company will further boost its dividend payments,... | I'm talking about healthcare giants AbbVie (NYSE: ABBV), Medtronic (NYSE: MDT), and Pfizer (NYSE: PFE). AbbVie AbbVie has made dividends its priority since its start, back in 2013 when it was spun off from Abbott Laboratories. AbbVie says that once earnings pick up, the company will further boost its dividend payments,... |
21,982 | 2023-12-07 00:00:00 UTC | AbbVie to focus on smaller deals after buying spree | ABBV | https://www.nasdaq.com/articles/abbvie-to-focus-on-smaller-deals-after-buying-spree | null | null | Adds details from conference call and background throughout, analyst comment in paragraph 8
Dec 7 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cereve... | "I would not anticipate similar sized transactions for the foreseeable future," said AbbVie's Chief Operating Officer Robert Michael on a conference call, referring to the company's $8.7 billion buyout of Cerevel Therapeutics CERE.O announced on Wednesday. "With additions of Cerevel and ImmunoGen, AbbVie is in a strong... | "I would not anticipate similar sized transactions for the foreseeable future," said AbbVie's Chief Operating Officer Robert Michael on a conference call, referring to the company's $8.7 billion buyout of Cerevel Therapeutics CERE.O announced on Wednesday. "With additions of Cerevel and ImmunoGen, AbbVie is in a strong... | Adds details from conference call and background throughout, analyst comment in paragraph 8 Dec 7 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cereve... | Adds details from conference call and background throughout, analyst comment in paragraph 8 Dec 7 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cereve... |
21,983 | 2023-12-07 00:00:00 UTC | Is AbbVie Stock a Buy Now? | ABBV | https://www.nasdaq.com/articles/is-abbvie-stock-a-buy-now-4 | null | null | Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. That's because it will need to become less reliant on Humira, its blockbuster rheumatoid arthritis drug, which is losing patent protection. One example of this came in 2020 when it closed on a massive... | Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. And while the company has a plan to make up for that void with other immunology drugs, Skyrizi and Rinvoq, it hasn't been winning over investors; year to date, share prices of AbbVie are down 11%. Abb... | AbbVie to acquire ImmunoGen On Nov. 30, AbbVie announced plans to acquire oncology company ImmunoGen (NASDAQ: IMGN) for approximately $10.1 billion. Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. The acquisition will help strengthen AbbVie's portf... | AbbVie to acquire ImmunoGen On Nov. 30, AbbVie announced plans to acquire oncology company ImmunoGen (NASDAQ: IMGN) for approximately $10.1 billion. AbbVie can benefit from more diversification For AbbVie, the acquisition makes a lot of sense: Its lack of diversification is one reason investors aren't overly bullish on... | AbbVie was a solid stock to buy even before this deal. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. |
21,984 | 2023-12-07 00:00:00 UTC | AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-to-acquire-cerevel-therapeutics-cere-for-%248.7b | null | null | AbbVie ABBV has announced a definitive agreement to acquire neuroscience drugmaker, Cerevel Therapeutics CERE, for $8.7 billion. This marks its second acquisition announcement in less than a fortnight.
The acquisition will strengthen AbbVie’s neuroscience pipeline by adding CERE’s novel pipeline candidates being studie... | However, some analysts found the move “bold” as AbbVie opted to buy Cerevel now rather than after top-line data read-outs in 2024, which would have been major catalysts for the stock. AbbVie ABBV has announced a definitive agreement to acquire neuroscience drugmaker, Cerevel Therapeutics CERE, for $8.7 billion. The acq... | AbbVie ABBV has announced a definitive agreement to acquire neuroscience drugmaker, Cerevel Therapeutics CERE, for $8.7 billion. On Nov 30, AbbVie announced a definitive agreement to acquire cancer biotech ImmunoGen IMGN for $10.1 billion, including its new ovarian cancer drug, Elahere. Click to get this free report No... | Cerevel's clinical-stage pipeline candidates, which AbbVie believes have multibillion-dollar sales potential, complement its marketed neuroscience drugs portfolio, representing a significant long-term growth opportunity for AbbVie. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Immuno... | AbbVie ABBV has announced a definitive agreement to acquire neuroscience drugmaker, Cerevel Therapeutics CERE, for $8.7 billion. Zacks Rank & A Key Pick AbbVie and Cerevel have a Zacks Rank #3 (Hold). The acquisition will strengthen AbbVie’s neuroscience pipeline by adding CERE’s novel pipeline candidates being studied... |
21,985 | 2023-12-06 00:00:00 UTC | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-wisdomtree-u.s.-high-dividend-etf-dhs-a-strong-etf-right-now-9 | null | null | Designed to provide broad exposure to the Style Box - Large Cap Value category of the market, the WisdomTree U.S. High Dividend ETF (DHS) is a smart beta exchange traded fund launched on 06/16/2006.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the ma... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.84% of total assets, followed by Chevron Corp (CVX) and Abbvie Inc (ABBV). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.84% of total assets, followed by Chevron Corp (CVX) and Abbvie Inc (ABBV). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... |
21,986 | 2023-12-06 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-12 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
21,987 | 2023-12-06 00:00:00 UTC | ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA | ABBV | https://www.nasdaq.com/articles/immunogen-imgn-gets-fda-priority-review-for-elahere-sbla | null | null | ImmunoGen, Inc. IMGN announced that the FDA accepted its supplemental biologics license application (“sBLA”), seeking to convert the accelerated approval for its sole marketed drug, Elahere (mirvetuximab soravtansine), to full approval for treating FRα-positive platinum-resistant ovarian cancer.
With the FDA granting a... | Image Source: Zacks Investment Research ImmunoGen stock received a boost last week when drug giant AbbVie ABBV announced a definitive agreement to acquire the company for $10.1 billion. Under the terms of the deal, the purchase price offered by ABBV of $31.26 represents a premium of almost 95% on ImmunoGen’s closing pr... | Click to get this free report ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Harpoon Therapeutics, Inc. (HARP) : Free Stock Analysis Report Avalo Therapeutics, Inc. (AVTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks ... | Click to get this free report ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Harpoon Therapeutics, Inc. (HARP) : Free Stock Analysis Report Avalo Therapeutics, Inc. (AVTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks ... | Image Source: Zacks Investment Research ImmunoGen stock received a boost last week when drug giant AbbVie ABBV announced a definitive agreement to acquire the company for $10.1 billion. Under the terms of the deal, the purchase price offered by ABBV of $31.26 represents a premium of almost 95% on ImmunoGen’s closing pr... |
21,988 | 2023-12-06 00:00:00 UTC | EXCLUSIVE-AbbVie nears roughly $8 billion for drug developer Cerevel-sources | ABBV | https://www.nasdaq.com/articles/exclusive-abbvie-nears-roughly-%248-billion-for-drug-developer-cerevel-sources | null | null | NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday.
AbbVie is in talks to pay around $45 per share for Cerev... | NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday. AbbVie is in talks to pay around $45 per share for Cerev... | NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday. AbbVie and Cerevel did not immediately respond to reques... | NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday. AbbVie is in talks to pay around $45 per share for Cerev... | NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday. AbbVie is in talks to pay around $45 per share for Cerev... |
21,989 | 2023-12-06 00:00:00 UTC | 7 High-Dividend Stocks to Buy for a Lifetime of Passive Income | ABBV | https://www.nasdaq.com/articles/7-high-dividend-stocks-to-buy-for-a-lifetime-of-passive-income | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
As investors, we always strive to build a well-balanced portfolio that can provide stability through various economic cycles. While high-flying growth stocks generate all the hype these days (and deservedly so), defensive dividend stocks remain essential to... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As one of the pharmaceutical sector’s largest players, AbbVie (NYSE:ABBV) provides immense dividend reliability. Even with the U.S. Humira patent expiration in play, AbbVie has only strengthened its cash generation capabilities. With its high 4.3% forward yield and Di... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As one of the pharmaceutical sector’s largest players, AbbVie (NYSE:ABBV) provides immense dividend reliability. Even with the U.S. Humira patent expiration in play, AbbVie has only strengthened its cash generation capabilities. With its high 4.3% forward yield and Di... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As one of the pharmaceutical sector’s largest players, AbbVie (NYSE:ABBV) provides immense dividend reliability. Even with the U.S. Humira patent expiration in play, AbbVie has only strengthened its cash generation capabilities. With its high 4.3% forward yield and Di... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As one of the pharmaceutical sector’s largest players, AbbVie (NYSE:ABBV) provides immense dividend reliability. Even with the U.S. Humira patent expiration in play, AbbVie has only strengthened its cash generation capabilities. With its high 4.3% forward yield and Di... |
21,990 | 2023-12-06 00:00:00 UTC | AbbVie to buy drug developer Cerevel for $8.7 billion | ABBV | https://www.nasdaq.com/articles/abbvie-to-buy-drug-developer-cerevel-for-%248.7-billion | null | null | Adds details on the deal and background
Dec 6 (Reuters) - AbbVie ABBV.N said on Wednesday it would buy Cerevel Therapeutics CERE.O for a total equity value of about $8.7 billion.
AbbVie would acquire all outstanding shares of Cerevel for $45 per share in cash, representing a premium of 22% to Wednesday's close.
Cerevel... | Adds details on the deal and background Dec 6 (Reuters) - AbbVie ABBV.N said on Wednesday it would buy Cerevel Therapeutics CERE.O for a total equity value of about $8.7 billion. AbbVie would acquire all outstanding shares of Cerevel for $45 per share in cash, representing a premium of 22% to Wednesday's close. One of ... | AbbVie would acquire all outstanding shares of Cerevel for $45 per share in cash, representing a premium of 22% to Wednesday's close. Adds details on the deal and background Dec 6 (Reuters) - AbbVie ABBV.N said on Wednesday it would buy Cerevel Therapeutics CERE.O for a total equity value of about $8.7 billion. Cerevel... | AbbVie would acquire all outstanding shares of Cerevel for $45 per share in cash, representing a premium of 22% to Wednesday's close. Adds details on the deal and background Dec 6 (Reuters) - AbbVie ABBV.N said on Wednesday it would buy Cerevel Therapeutics CERE.O for a total equity value of about $8.7 billion. Cerevel... | Adds details on the deal and background Dec 6 (Reuters) - AbbVie ABBV.N said on Wednesday it would buy Cerevel Therapeutics CERE.O for a total equity value of about $8.7 billion. AbbVie would acquire all outstanding shares of Cerevel for $45 per share in cash, representing a premium of 22% to Wednesday's close. Cerevel... |
21,991 | 2023-12-06 00:00:00 UTC | AbbVie To Acquire Cerevel Therapeutics In $8.7 Bln Deal | ABBV | https://www.nasdaq.com/articles/abbvie-to-acquire-cerevel-therapeutics-in-%248.7-bln-deal | null | null | (RTTNews) - AbbVie Inc. (ABBV) agreed to acquire Cerevel Therapeutics (CERE) for $45.00 per share in cash, valuing the company at about $8.7 billion.
CERE closed Wednesday's regular trading at $36.93 up $1.34 or 3.77%. In the after-hours trading, the stock further gained $5.82 or 15.76%.
AbbVie will acquire Cerevel The... | (RTTNews) - AbbVie Inc. (ABBV) agreed to acquire Cerevel Therapeutics (CERE) for $45.00 per share in cash, valuing the company at about $8.7 billion. AbbVie will acquire Cerevel Therapeutics' neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including sch... | (RTTNews) - AbbVie Inc. (ABBV) agreed to acquire Cerevel Therapeutics (CERE) for $45.00 per share in cash, valuing the company at about $8.7 billion. AbbVie will acquire Cerevel Therapeutics' neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including sch... | (RTTNews) - AbbVie Inc. (ABBV) agreed to acquire Cerevel Therapeutics (CERE) for $45.00 per share in cash, valuing the company at about $8.7 billion. AbbVie will acquire Cerevel Therapeutics' neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including sch... | (RTTNews) - AbbVie Inc. (ABBV) agreed to acquire Cerevel Therapeutics (CERE) for $45.00 per share in cash, valuing the company at about $8.7 billion. AbbVie will acquire Cerevel Therapeutics' neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including sch... |
21,992 | 2023-12-06 00:00:00 UTC | EXCLUSIVE-AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources | ABBV | https://www.nasdaq.com/articles/exclusive-abbvie-nears-roughly-%248-billion-deal-for-drug-developer-cerevel-sources | null | null | By David Carnevali
NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday.
The acquisition would come just days ... | By David Carnevali NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday. The acquisition would come just days ... | By David Carnevali NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday. The acquisition would come just days ... | By David Carnevali NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday. AbbVie is in talks to pay around $45 ... | By David Carnevali NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday. The acquisition would come just days ... |
21,993 | 2023-12-05 00:00:00 UTC | Johnson & Johnson forecasts as much as 6% sales growth in 2024 | ABBV | https://www.nasdaq.com/articles/johnson-johnson-forecasts-as-much-as-6-sales-growth-in-2024-0 | null | null | By Patrick Wingrove and Bhanvi Satija
Dec 5 (Reuters) - Johnson & Johnson JNJ.N on Tuesday forecast revenue growth of 5-6% for 2024, its first full year after hiving off its consumer health unit, on strong demand for cancer treatments Darzalex and Carvykti, and blockbuster psoriasis drug Stelara.
The company also forec... | The company also forecast 2024 adjusted operating profit of $10.55 to $10.75 per share, including a 15-cent impact from its recent acquisition of private medical device maker Laminar. "I think they can earn closer to $10.85 vs the $10.55-10.75 guidance," said Jeff Jonas, portfolio manager at Gabelli Funds, adding the c... | By Patrick Wingrove and Bhanvi Satija Dec 5 (Reuters) - Johnson & Johnson JNJ.N on Tuesday forecast revenue growth of 5-6% for 2024, its first full year after hiving off its consumer health unit, on strong demand for cancer treatments Darzalex and Carvykti, and blockbuster psoriasis drug Stelara. The company expects op... | By Patrick Wingrove and Bhanvi Satija Dec 5 (Reuters) - Johnson & Johnson JNJ.N on Tuesday forecast revenue growth of 5-6% for 2024, its first full year after hiving off its consumer health unit, on strong demand for cancer treatments Darzalex and Carvykti, and blockbuster psoriasis drug Stelara. J&J Chief Financial Of... | The company also forecast 2024 adjusted operating profit of $10.55 to $10.75 per share, including a 15-cent impact from its recent acquisition of private medical device maker Laminar. Stelara is also expected to face competition in the United States beginning in 2025. The company said over 10 of its products had the po... |
21,994 | 2023-12-05 00:00:00 UTC | AbbVie To Collaborate With BigHat To Discover Next-Gen Therapeutic Antibodies | ABBV | https://www.nasdaq.com/articles/abbvie-to-collaborate-with-bighat-to-discover-next-gen-therapeutic-antibodies | null | null | (RTTNews) - AbbVie Inc. (ABBV) and BigHat Biosciences, Monday announced a research collaboration for next-generation therapeutic antibodies in oncology and neuroscience. The combination is expected to utilize BigHat's Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab.
As p... | (RTTNews) - AbbVie Inc. (ABBV) and BigHat Biosciences, Monday announced a research collaboration for next-generation therapeutic antibodies in oncology and neuroscience. The combination is expected to utilize BigHat's Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab. As p... | (RTTNews) - AbbVie Inc. (ABBV) and BigHat Biosciences, Monday announced a research collaboration for next-generation therapeutic antibodies in oncology and neuroscience. As per the agreement, BigHat will receive an upfront payment of $30 million and an additional milestone payment of approximately $325 million, with th... | (RTTNews) - AbbVie Inc. (ABBV) and BigHat Biosciences, Monday announced a research collaboration for next-generation therapeutic antibodies in oncology and neuroscience. As per the agreement, BigHat will receive an upfront payment of $30 million and an additional milestone payment of approximately $325 million, with th... | (RTTNews) - AbbVie Inc. (ABBV) and BigHat Biosciences, Monday announced a research collaboration for next-generation therapeutic antibodies in oncology and neuroscience. The combination is expected to utilize BigHat's Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab. As p... |
21,995 | 2023-12-05 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-11 | null | null | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this drugmaker have returned +2.1% over the past month versus the Zacks S&P 500 composite's +5.1% change. The Zacks Large C... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie ... | Last Reported Results and Surprise History AbbVie reported revenues of $13.93 billion in the last reported quarter, representing a year-over-year change of -6%. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gain... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs,... | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 2.8% over this period. AbbVie is expected to post earnings of $2.93 per share for the current quarter, representing a year-over-year change of -18.6%. |
21,996 | 2023-12-05 00:00:00 UTC | Johnson & Johnson forecasts as much as 6% sales growth in 2024 | ABBV | https://www.nasdaq.com/articles/johnson-johnson-forecasts-as-much-as-6-sales-growth-in-2024 | null | null | Dec 5 (Reuters) - Johnson & Johnson JNJ.N on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara.
The company has narrowed its focus on its drugs and medical devices business since it hived of... | "We think we're very well positioned, even in spite of what will be the beginning of some biosimilar entrants to Stelara outside the US in mid to second half of 2024," Chief Financial Officer Joseph Wolk told Reuters. J&J, which plans to launch at least 20 new therapies by 2030, said over 10 of its products had the pot... | Dec 5 (Reuters) - Johnson & Johnson JNJ.N on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara. J&J, which plans to launch at least 20 new therapies by 2030, said over 10 of its products had... | Dec 5 (Reuters) - Johnson & Johnson JNJ.N on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara. Sales of blockbuster psoriasis treatment Stelara in Europe are expected to come under pressure... | Dec 5 (Reuters) - Johnson & Johnson JNJ.N on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara. The company has narrowed its focus on its drugs and medical devices business since it hived of... |
21,997 | 2023-12-04 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-27 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
21,998 | 2023-12-04 00:00:00 UTC | SPLG, HD, COST, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/splg-hd-cost-abbv%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 ETF (Symbol: SPLG) where we have detected an approximate $278.0 million dollar inflow -- that's a 1.2% increase week over week in outstanding units (from 427,100,000 t... | Among the largest underlying components of SPLG, in trading today Home Depot Inc (Symbol: HD) is up about 1.3%, Costco Wholesale Corp (Symbol: COST) is off about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.8%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed t... | Among the largest underlying components of SPLG, in trading today Home Depot Inc (Symbol: HD) is up about 1.3%, Costco Wholesale Corp (Symbol: COST) is off about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.8%. For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year pr... | Among the largest underlying components of SPLG, in trading today Home Depot Inc (Symbol: HD) is up about 1.3%, Costco Wholesale Corp (Symbol: COST) is off about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of SPLG, in trading today Home Depot Inc (Symbol: HD) is up about 1.3%, Costco Wholesale Corp (Symbol: COST) is off about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... |
21,999 | 2023-12-04 00:00:00 UTC | Analysts Anticipate MGC Will Reach $181 | ABBV | https://www.nasdaq.com/articles/analysts-anticipate-mgc-will-reach-%24181-0 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Mega Cap ETF (Symbol: ... | Vanguard Mega Cap ETF MGC $163.80 $180.73 10.34% AbbVie Inc ABBV $143.41 $171.94 19.89% Humana Inc. HUM $495.21 $587.94 18.73% T-Mobile US Inc TMUS $152.23 $180.53 18.59% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of MGC's underlying ... | Three of MGC's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Humana Inc. (Symbol: HUM), and T-Mobile US Inc (Symbol: TMUS). Vanguard Mega Cap ETF MGC $163.80 $180.73 10.34% AbbVie Inc ABBV $143.41 $171.94 19.89% Humana Inc. HUM $495.21 $587.94 18.73% T-Mobile US I... | Three of MGC's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Humana Inc. (Symbol: HUM), and T-Mobile US Inc (Symbol: TMUS). Although ABBV has traded at a recent price of $143.41/share, the average analyst target is 19.89% higher at $171.94/share. Below is a twelve... | Vanguard Mega Cap ETF MGC $163.80 $180.73 10.34% AbbVie Inc ABBV $143.41 $171.94 19.89% Humana Inc. HUM $495.21 $587.94 18.73% T-Mobile US Inc TMUS $152.23 $180.53 18.59% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of MGC's underlying ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.